Professor James Catto

MB ChB PhD FRCS(Urol)

Clinical Medicine, School of Medicine and Population Health

Professor of Urology

James Catto, Professor in Urological Surgery

j.catto@sheffield.ac.uk
+44 114 215 9002

+44 114 271 2268 (Fax)

GU19, G Floor, The Medical School

Full contact details

Professor James Catto
Clinical Medicine, School of Medicine and Population Health
GU19, G Floor
The Medical School
Beech Hill Road
Sheffield
S10 2RX

Profile

For enquiries please contact - ClinMed-Operational@sheffield.ac.uk

James Catto is NIHR Research Professor, Professor of Urology at the University of Sheffield and an Honorary Consultant Urological Surgeon at Sheffield Teaching Hospitals NHS Trust. He holds posts as an Honorary Senior Clinical Research fellow at the University of Oxford and Honorary Clinical Professor, Division of Surgery & Interventional Science, University College London. He qualified from Leeds University in 1994 and trained in York and Sheffield, UK before a fellowship in Brisbane, Australia.

James obtained a PhD in 2004 and runs a research team investigating the biology and management of urological cancers. He was awarded the European Association of Urology Best Thesis prize and the Bard Medal from BAUS for his PhD studies. In 2007 he was EAU-AUA exchange fellow with visits to the Johns Hopkins Medical School, The University of Chicago, Loyola University and The University of California, San Francisco. In 2010, he was awarded the Crystal Matula by the EAU, the Astellas Education Foundation award in 2011 and the Golden Telescope by BAUS in 2014.

James has raised over £26 million in peer-reviewed funding, published more than 300 primary research manuscripts, and has more than 30,000 citations on Google and an H factor of 72 on Scopus. His research funding includes a NIHR Research Professorship, a GSK Clinician Scientist fellowship, an MRC Clinical Research Fellowship, and grants from NIHR/MRC, The Wellcome Trust, CRUK, European Union, Royal College of Surgeons, The Urological Foundation and Yorkshire Cancer Research.

James is Editor In Chief of European Urology (2019 Impact factor 18.728). Please see the European Urology website for further details.

Research interests

James leads on Urology research, encompassing NIHR Clinical Lecturers, NIHR ACFs, post-docs, technicians, research nurses and PhD students. The team research the translational application of molecular biology to urological malignancies, in particular Bladder and Prostate Cancer, and partake in clinical trials focused on improving the care of patients with these cancers. James's particular interest is in the epigenetic alterations seen within these tumours.

James is also lead for The University of Sheffield’s Cancer Research program. This multimodal data-driven patient-focussed program aims to improve survival for many common cancers across Yorkshire and create world leading expertise within Sheffield.

Current projects

James is currently Chief Investigator for i). GUSTO - Genotype of Urothelial cancer: Stratified Treatment and Oncological outcomes: Phase 2 study (funded by the MRC/NIHR), ii). iROC - A multicentre randomised controlled trial to compare the efficacy of Robotically Assisted Radical Cystectomy and intracorporeal urinary diversion with Open Radical Cystectomy in patients with bladder cancer (Funded by TUF), iii). YorkSure - Early detection of bladder cancer in Yorkshire: Feasibility assessments for implementing a targeted study in populations with high disease specific mortality risk (Funded by Yorkshire Cancer Research), iv). FINESSE - Increasing compliance with Active surveillance: A randomised trial evaluating the role of Finasteride (Funded by Yorkshire Cancer Research), v). Improving the outcomes from Bladder Cancer through the application of genomic stratification and development of novel agents (NIHR Research Professorship) and vi). Life and Bladder Cancer: The Yorkshire Cancer Research Bladder Cancer Patient Reported Outcomes Survey. (Funded by Yorkshire Cancer Research).

Publications

Show: Featured publications All publications

Featured publications

Journal articles

Catto JWF, Khetrapal P, Ricciardi F, Ambler G, Williams NR, Al-Hammouri T, Khan MS, Thurairaja R, Nair R, Feber A , Dixon S et al (2022) Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer : a randomized clinical trial. JAMA. View this article in WRRO
Hussain SA, Lester JF, Jackson R, Gornall M, Qureshi M, Elliott A, Crabb SJ, Huddart RA, Vasudev N, Birtle AJ , Worlding J et al (2022) Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE) : a double-blind, randomised, phase 2 trial. The Lancet Oncology, 23(5), 650-658. View this article in WRRO
Bryan RT, Liu W, Pirrie SJ, Amir R, Gallagher J, Hughes AI, Jefferson KP, Knight A, Nanton V, Mintz HP , Pope AM et al (2021) Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study. European Urology.
Catto JWF, Downing A, Mason S, Wright P, Absolom K, Bottomley S, Hounsome L, Hussain S, Varughese M, Raw C , Kelly P et al (2021) Quality of life after bladder cancer: a cross-sectional survey of patient-reported outcomes. European Urology. View this article in WRRO
Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2021) Phase I trial of DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine for solid malignancies including urothelial carcinoma (SPIRE). Clinical Cancer Research. View this article in WRRO
Catto JWF, Gordon K, Collinson M, Poad H, Twiddy M, Johnson M, Jain S, Chahal R, Simms M, Dooldeniya M , Bell R et al (2020) Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-feasibility study. Journal of Clinical Oncology. View this article in WRRO
Reed O, Jubber I, Griffin J, Noon A, Goodwin L, Hussain S, Cumberbatch M & Catto J (2020) Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes. PLoS ONE, 15(10). View this article in WRRO
Williams SB, Cumberbatch MGK, Kamat AM, Jubber I, Kerr PS, McGrath JS, Djaladat H, Collins JW, Packiam VT, Steinberg GD , Lee E et al (2020) Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. European Urology, 78(5), 719-730.
Cappuccini F, Bryant R, Pollock E, Carter L, Verrill C, Hollidge J, Poulton I, Baker M, Mitton C, Baines A , Meier A et al (2020) Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial. Journal for ImmunoTherapy of Cancer, 8(1), e000928-e000928.
Wallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, Morgan TM, Mottet N, Gillessen S, Bossi A , Roupret M et al (2020) Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. European Urology, 78(1), 29-42.
Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, Harris C, Winterbottom A, Blacker A, Catto JWF , Chakraborti P et al (2020) Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. The Lancet, 395(10232), 1268-1277. View this article in WRRO
Mostafid AH, Porta N, Cresswell J, Griffiths TRL, Kelly JD, Penegar SR, Davenport K, McGrath JS, Campain N, Cooke P , Masood S et al (2020) CALIBER - A phase II randomised feasibility trial of chemoablation with mitomycin versus surgical management in low risk non-muscle invasive bladder cancer. BJU International. View this article in WRRO
Pang KH, Novara GH, Din OS, Morgan SL, Noon AP, Catto JWF & Rosario DJ (2019) Long term survival after radical cystectomy with respect to centralisation: Outcomes from 1110 patients treated at a single high-volume centre. European Urology Supplements, 18(1), e1134-e1134.
Downing A, Wright P, Hounsome L, Selby P, Wilding S, Watson E, Wagland R, Kind P, Donnelly DW, Butcher H , Catto JWF et al (2019) Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study. The Lancet Oncology, 20(3), 436-447. View this article in WRRO
Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, Kiemeney L, Lotan Y, Pang K, Silverman DT , Znaor A et al (2018) Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. European Urology. View this article in WRRO
Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, Huddart R, Kennish S, Lerner S, Montironi R , Muglia VF et al (2018) Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). European Urology, 74(3), 294-306. View this article in WRRO
Catto JWF, Khetrapal P, Ambler G, Sarpong R, Potyka I, Khan MS, Tan M, Feber A, Bourke L, Noon AP , Dixon S et al (2018) Multidomain Quantitative Recovery Following Radical Cystectomy for Patients Within the Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion Versus Open Radical Cystectomy Randomised Controlled Trial: The First 30 Patients. European Urology, 74(4), 531-534.
Pang KH, Groves R, Venugopal S, Noon AP & Catto JWF (2018) Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy. European Urology, 73(3), 363-371. View this article in WRRO
Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R , Castro MAA et al (2017) Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell, 171(3), 540-556.e25.
Bourke L, Bauld L, Bullen C, Cumberbatch M, Giovannucci E, Islami F, McRobbie H, Silverman DT & Catto JWF (2017) E-cigarettes and Urologic Health: A Collaborative Review of Toxicology, Epidemiology, and Potential Risks. European Urology, 71(6), 915-923.
Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM , Oxley J et al (2016) 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. New England Journal of Medicine, 375(15), 1415-1424. View this article in WRRO
Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, Blazeby JM, Peters TJ, Holding P, Bonnington S , Lennon T et al (2016) Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. New England Journal of Medicine, 375(15), 1425-1437. View this article in WRRO
Cumberbatch MG, Rota M, Catto JWF & La Vecchia C (2016) The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. European Urology, 70(3), 458-466. View this article in WRRO
Cumberbatch MG, Windsor-Shellard B & Catto JWF (2016) The contemporary landscape of occupational bladder cancer within the United Kingdom: a meta-analysis of risks over the last 80 years. BJU International. View this article in WRRO
Cumberbatch MGK, Cox A, Teare D & Catto JWF (2015) Contemporary Occupational Carcinogen Exposure and Bladder Cancer. JAMA Oncology, 1(9), 1282-1290. View this article in WRRO

All publications

Books

Pang KH, Osman NI, Catto JWF & Chapple CR (2021) Preface.
Pang KH, Osman NI, Catto JWF & Chapple CR () Basic Urological Sciences. CRC Press.

Journal articles

Li R, Linscott J, Catto JWF, Daneshmand S, Faltas BM, Kamat AM, Meeks JJ, Necchi A, Pradere B, Ross JS , van der Heijden MS et al (2024) FGFR Inhibition in Urothelial Carcinoma. European Urology.
Powles TB, van der Heijden MS, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L, Wiechno P, Atduev V , Kann AG et al (2024) LBA5 A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA). Annals of Oncology, 35, S1271-S1271.
Bravo L, Simões JF, Cardoso VR, Adisa A, Aguilera ML, Arnaud A, Biccard B, Calvache J, Chernbumroong S, Elhadi M , Ghosh D et al (2024) A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts. The Lancet Digital Health, 6(7), e507-e519.
Bancroft EK, Page EC, Brook MN, Pope J, Thomas S, Myhill K, Helfand BT, Talaty P, Ong K, Douglas E , Cook J et al (2024) The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers. BJU International, 134(3), 484-500.
Crabb SJ, Hussain SA, Oughton JB, Swain J, Cairns DA, Collinson M, Ainsworth G, McCready D, Griffin J, Heath P , Quayle L et al (2024) Use of gene expression patterns to identify unique molecular subtypes in muscle invasive bladder cancer: GUSTO.. Journal of Clinical Oncology, 42(16_suppl), TPS4621-TPS4621.
Absolom K, Rogers Z, Catto JWF, Bottomley S, Glaser A & Downing A (2024) Decision Regret Regarding Treatment Choices 1 Year After a New Diagnosis of Bladder Cancer. European Urology.
Khetrapal P, Liu Y, Ambler G, Williams NR, Sridhar A, Khan MS, Ahmad I, Charlesworth P, Kotwal S, Rowe E , Hanchanale V et al (2024) PD36-04 REMOTE DIGITAL SURVEILLANCE AND MACHINE LEARNING MODELLING TO PREDICT SURVIVAL FOLLOWING RADICAL CYSTECTOMY FOR BLADDER CANCER—A SECONDARY OUTCOME ANALYSIS OF THE IROC TRIAL. Journal of Urology, 211(5S).
Khetrapal P, Liu Y, Ambler G, Williams NR, Sridhar A, Khan MS, Ahmed I, Charlesworth P, Kotwal S, Rowe E , Koupparis A et al (2024) Digital remote monitoring and Machine Learning (ML) modeling to predict survival following radical cystectomy for bladder cancer – a secondary outcome analysis of the iROC trial. European Urology, 85, S929-S930.
Catto JWF, Necchi A, Powles T, Guerrero-Ramos F, Simone G, Shore N, Salinas JS, Merseburger AS, Roumiguie M, Hiroshi K , Morris DM et al (2024) SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette–Guérin in patients with BCG-naive high-risk non–muscle-invasive bladder cancer. European Urology, 85, S1505-S1505.
Panebianco V, Briganti A, Boellaard TN, Catto J, Compera E, Efstathiou J, Van Der Heijden AG, Giannarini G, Girometti R, Mertens L , Takeuchi M et al (2024) Clinical Application of Bladder MRI and Vesical Imaging-Reporting And Data System. European Urology, 85, S1874-S1875.
Catto JWF, Hussain SA, Tran B, Pignot G, Master V, Rouprêt M, Tubaro A, Shimizu N, Vasdev N, Nishiyama H , Daneshmand S et al (2024) UPDATED EFFICACY AND SAFETY OF ORAL ERDAFITINIB IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE, HIGH-RISK NON-MUSCLE–INVASIVE BLADDER CANCER WITH FGFR3/2 ALTERATIONS IN THOR-2 COHORT 2. Urologic Oncology: Seminars and Original Investigations, 42, S53-S53.
Sivakumaar K, Griffin J, Schofield E, Catto JWF & Jubber I (2024) Gene of the month: the uroplakins. Journal of Clinical Pathology, 77(5), 291-296.
Griffin J, Down J, Quayle LA, Heath PR, Gibb EA, Davicioni E, Liu Y, Zhao X, Swain J, Wang D , Hussain S et al (2024) Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial. The Journal of Pathology: Clinical Research, 10(2). View this article in WRRO
Qureshi M, Rehan A, Mok WK, Salawu A, Goktas Aydin S, Tay J, Hubbard R, Catto JWF & Hussain SA (2024) Thromboembolic events associated with neoadjuvant chemotherapy for muscle invasive cancer of the bladder.. Journal of Clinical Oncology, 42(4_suppl), 586-586.
Rehan A, Qureshi M, Goktas Aydin S, O'Connor K, Serra M, Charnley N, Spurgeon L, Muazzam I, Bansal V, Vasudev N , Coe F et al (2024) Real world outcomes for maintenance avelumab treatment in locally advanced/metastatic urothelial cancer after platinum-based chemotherapy.. Journal of Clinical Oncology, 42(4_suppl), 584-584.
Hussain SA, Oughton JB, Smith Whelan R, Green A, Hubbard R, Kennish S, Senior E, Kendall J, McCready D, Collinson FJ , Griffin J et al (2024) INVEST: A phase Ib window of opportunity study of atezolizumab administered either intravesically or direct tumour injection in patients with bladder cancer prior to radical cystectomy.. Journal of Clinical Oncology, 42(4_suppl), TPS710-TPS710.
Gore JL, Follmer K, Reynolds J, Nash M, Anderson CB, Catto JWF, Chamie K, Daneshmand S, Dickstein R, Garg T , Gilbert SM et al (2023) Interruptions in bladder cancer care during the COVID-19 public health emergency. Urologic Oncology: Seminars and Original Investigations.
Nanton V, Bryan RT, Pope AM, Hughes A, Jefferson K, Catto JWF, Knight A, Gallagher J, Mintz HP, Pirrie SJ , Liu W et al (2023) Boosting and broadening recruitment to UK cancer trials: towards a blueprint for action. BMJ Oncology, 2(1), e000092-e000092.
Khetrapal P, Bains PS, Jubber I, Ambler G, Williams NR, Brew-Graves C, Sridhar A, Ta A, Kelly JD & Catto JWF (2023) Digital Tracking of Patients Undergoing Radical Cystectomy for Bladder Cancer: Daily Step Counts Before and After Surgery Within the iROC Randomised Controlled Trial. European Urology Oncology.
Catto JWF, Tran B, Rouprêt M, Gschwend JE, Loriot Y, Nishiyama H, Redorta JP, Daneshmand S, Hussain SA, Cutuli HJ , Procopio G et al (2023) Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer. Annals of Oncology.
Catto JWF, Tran B, Roupret M, Gschwend JE, Loriot Y, Nishiyama H, Palou J, Daneshmand S, Hussain SA, Cutuli HJ , Procopio G et al (2023) LBA102 THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment. Annals of Oncology, 34, S1341-S1342.
Necchi A, Catto JWF, Powles TB, Guerrero-Ramos F, Simone G, Shore ND, Salinas J, Merseburger AS, Roumiguié M, Kitamura H , Morris D et al (2023) 2407TiP SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Guérin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC). Annals of Oncology, 34, S1224-S1224.
Catto JWF, North B, Goff M, Carter A, Sleeth M, Mandrik O, Chilcott J, Sasieni P & Cumberbatch MGK (2023) Protocol for the YORKSURe prospective multistage study testing the feasibility for early detection of bladder cancer in populations with high disease-specific mortality risk. BMJ Open, 13(9), e076612-e076612.
Khetrapal P, Wong JKL, Tan WP, Rupasinghe T, Tan WS, Williams SB, Boorjian SA, Wijburg C, Parekh DJ, Wiklund P , Vasdev N et al (2023) Corrigendum to “Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials” [Eur Urol. 2023;84:393–405]. European Urology, 84(4), e98-e99.
Newton RU, Hart NH, Kenfield SA, Galvao DA, Courneya KS, Ryan CM, Chan JM, Catto JWF, Winters-Stone KM, Van Hemelrijck M , Wylie H et al (2023) Cardiopulmonary exercise testing of patients with metastatic castrate-resistant prostate cancer as screening for vigorous exercise medicine prescription.. JCO Global Oncology, 9(Supplement_1), 80-80.
Dixon S, Hill H, Flight L, Khetrapal P, Ambler G, Williams NR, Brew-Graves C, Kelly JD, Catto JWF, Groves ER , Goodwin L et al (2023) Cost-effectiveness of robot-assisted radical cystectomy vs open radical cystectomy for patients with bladder cancer. JAMA Network Open, 6(6). View this article in WRRO
Jubber I, Morhardt DR, Griffin J, Cumberbatch M, Glover M, Zheng Y, Rehman I, Loynes C, Hussain SA, Renshaw SA , Leach SD et al (2023) Analysis of the distal urinary tract in larval and adult zebrafish reveals homology to the human system. Disease Models & Mechanisms, dmm.050110.
Jubber I, Ong S, Bukavina L, Black PC, Compérat E, Kamat AM, Kiemeney L, Lawrentschuk N, Lerner SP, Meeks JJ , Moch H et al (2023) Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors. European Urology, 84(2), 176-190.
Khetrapal P, Wong JKL, Tan WP, Rupasinghe T, Tan WS, Williams SB, Boorjian SA, Wijburg C, Parekh DJ, Wiklund P , Vasdev N et al (2023) Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials. European Urology, 84(4), 393-405.
Catto JWF, Rogers Z, Downing A, Mason SJ, Jubber I, Bottomley S, Conner M, Absolom K & Glaser A (2023) Lifestyle Factors in Patients with Bladder Cancer: A Contemporary Picture of Tobacco Smoking, Electronic Cigarette Use, Body Mass Index, and Levels of Physical Activity. European Urology Focus.
Khetrapal P, Catto J, Ambler G, Williams N, Al-Hammouri T, Khan MS, Thurairaja R, Nair R, Nathan S, Sridhar A , Ahmad I et al (2023) PD36-12 MEASURING OBJECTIVE RECOVERY OF ACTIVITY LEVELS USING WEARABLE DEVICES FOLLOWING OPEN VS INTRACORPOREAL ROBOTIC CYSTECTOMY: SECONDARY OUTCOMES ANALYSIS OF THE IROC RANDOMIZED TRIAL. Journal of Urology, 209(Supplement 4).
Hof JP, Vermeulen SH, van der Heijden AG, Verhaegh GW, Dyrskjøt L, Catto JWF, Mengual L, Bryan RT, Fleshner NE, Kiemeney LALM & Galesloot TE (2023) An Association Study of Germline Variants in Bladder Cancer-Related Genes with the Prognosis of Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 9(1), 59-71.
Donovan JL, Hamdy FC, Lane JA, Young GJ, Metcalfe C, Walsh EI, Davis M, Steuart-Feilding T, Blazeby JM, Avery KNL , Martin RM et al (2023) Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment. NEJM Evidence, 2(4).
Mandrik O, Hahn AI, Catto JWF, Zauber AG, Cumberbatch M & Chilcott J (2023) Critical appraisal of decision models used for the economic evaluation of bladder cancer screening and diagnosis: a systematic review. PharmacoEconomics, 41(6), 633-650. View this article in WRRO
Bryant RJ, Yamamoto H, Eddy B, Kommu S, Narahari K, Omer A, Leslie T, Catto JWF, Rosario DJ, Good D , Gray R et al (2023) Protocol for the TRANSLATE prospective, multicentre, randomised clinical trial of prostate biopsy technique. BJU International.
Niazi T, McBride SM, Williams S, Davis ID, Stockler MR, Martin AJ, Chung HT, Roncolato F, Ebacher A, Khoo E , Martin J et al (2023) DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer.. Journal of Clinical Oncology, 41(6_suppl), TPS396-TPS396.
Kamat AM, Steinberg GD, Inman BA, Kates MR, Uchio EM, Porten SP, Roupret M, Redorta J, Catto JWF, Kulkarni GS , Powles T et al (2023) Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)—Trial in progress.. Journal of Clinical Oncology, 41(6_suppl), TPS582-TPS582.
Catto JWF, Tran B, Master VA, Roupret M, Pignot G, Tubaro A, Shimizu N, Vasdev N, Gschwend JE, Loriot Y , Nishiyama H et al (2023) Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 2 interim analysis results.. Journal of Clinical Oncology, 41(6_suppl), 503-503.
Cooper OAE, Ghatnekar O, Piglowska N, Smith CA, Swinburn P, Catto JWF, Niegisch G & Jakobsen JS (2023) Elicitation of health state utilities associated with progression from Bacillus Calmette-Guerin (BCG) unresponsive Non-muscle Invasive Bladder Cancer (NMIBC). PharmacoEconomics - Open.
Khetrapal P, Catto JWF, Ambler G, Williams NR, Al-Hammouri T, Khan MS, Thurairaja R, Nair R, Nathan S, Sridhar A , Ahmed I et al (2023) Comparing objective recovery of activity levels using wearable devices in open vs. intracorporeal robotic cystectomy: An analysis of the secondary outcomes of the iROC randomized trial. European Urology, 83, S219-S220.
Collacott H, Krucien N, Heidenreich S, Catto JWF & Ghatnekar O (2023) Patient Preferences for Treatment of Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: A Cross-country Choice Experiment. European Urology Open Science, 49, 92-99.
Antonelli L, Sebro K, Lahmar A, Black PC, Ghodoussipour S, Hamilton-Reeves JM, Shah J, Bente Thoft J, Lerner SP, Llorente C , Lucca I et al (2023) Association Between Antibiotic Prophylaxis Before Cystectomy or Stent Removal and Infection Complications: A Systematic Review. European Urology Focus, 9(4), 631-636.
Rammant E, Fox L, Beyer K, Aaronson NK, Chaloner R, De Padova S, Liedberg F, Wintner LM, Decaestecker K, Fonteyne V , Perdek N et al (2023) The current use of the EORTC QLQ-NMIBC24 and QLQ-BLM30 questionnaires for the assessment of health-related quality of life in bladder cancer patients: a systematic review. Quality of Life Research, 32(8), 2127-2135.
Stenzl A (2023) Re. Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients with Bladder Cancer: A Randomized Clinical Trial. European Urology, 83(1), 90-91.
Conroy S, Pang K, Jubber I, Hussain SA, Rosario DJ, Cumberbatch MG, Catto JWF & Noon AP (2022) Hyperthermic intravesical chemotherapy with mitomycin‐C for the treatment of high‐risk non‐muscle‐invasive bladder cancer patients. BJUI Compass. View this article in WRRO
Catto JWF, Khetrapal P & Ambler G (2022) Effect of Robot-Assisted Radical Cystectomy vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer—Reply. JAMA, 328(12), 1258-1258.
Catto JWF (2022) Monkeypox and the Urologist: Playing an Important Role in This Emerging Global Outbreak. European Urology.
Catto JWF, Khetrapal P, Ambler G, Williams NR, Brew-Graves C & Kelly JD (2022) Reply to Bernardo Rocco and Maria Chiara Sighinolfi’s Letter to the Editor re: James W.F. Catto, Pramit Khetrapal, Federico Ricciardi, et al. Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients with Bladder Cancer: A Randomized Clinical Trial. JAMA 2022;327:2092–103. European Urology.
James ND, Pirrie S, Liu W, Jefferson K, Gallagher J, Hughes A, Knight A, Nanton V, Mintz HP, Pope A , Doyle H et al (2022) 1733MO First results from BladderPath: A randomised trial of MRI versus cystoscopic staging for newly diagnosed bladder cancer. Annals of Oncology, 33, S1330-S1330.
(2022) Updates on bladder, kidney and prostate cancers. BJU International, 130(3), 275-276.
Catto JWF, Khetrapal P, Ambler G, Williams NR, Brew-Graves C & Kelly JD (2022) Reply to Andreas Skolarikos’s Words of Wisdom re: Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients with Bladder Cancer: A Randomized Clinical Trial. Eur Urol. In press. European Urology.
Jubber I, Rogers Z, Catto JWF, Bottomley S, Glaser A, Downing A & Absolom K (2022) Sexual activity, function and dysfunction after a diagnosis of bladder cancer. The Journal of Sexual Medicine, 19(9), 1431-1441. View this article in WRRO
Jubber I, Mitchell S, Hussain S, Tsoi H, Catto JWF & Cumberbatch MG (2022) Social deprivation and bladder cancer: cause or effect for disparities in survival for affected women. BJU International, 130(3), 301-302.
Cooper O, Rentz A, Piglowska N, Smith C, Jakobsen J, Catto J, Niegisch G, Ghatnekar O & Swinburn P (2022) P7 Elicitation of Health State Utilities Associated Progression from BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Health States. Value in Health, 25(7), S288-S288.
Fotopoulou C, Khan T, Bracinik J, Glasbey J, Abu-Rustum N, Chiva L, Fagotti A, Fujiwara K, Ghebre R, Gutelkin M , Konney TO et al (2022) Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study. American Journal of Obstetrics and Gynecology, 227(5), 735.e1-735.e25.
Freudenburg E, Bagheri I, Srinivas S, Martinez A, Putluri N, Klaassen Z, Kamat AM, Konety BR, Kim WY, Dyrskjøt L , McConkey DJ et al (2022) Race reporting and disparities regarding clinical trials in bladder cancer: a systematic review. Cancer Causes & Control, 33(8), 1071-1081.
Niazi T, McBride SM, Williams S, Davis ID, Stockler MR, Martin AJ, Bracken K, Roncolato F, Horvath L, Sengupta S , Martin J et al (2022) DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. Journal of Clinical Oncology, 40(16_suppl), TPS5103-TPS5103.
Conroy S, Hubbard R, Noon AP, Hussain SA, Griffin J, Kennish S & Catto JWF (2022) Case of the month from the University of Sheffield, UK : Expediting definitive treatment in patients with invasive bladder cancer: an MRI ‐guided pathway. BJU International, 129(6), 691-694.
Catto JWF, Khetrapal P, Ricciardi F, Ambler G, Williams NR, Al-Hammouri T, Khan MS, Thurairaja R, Nair R, Feber A , Dixon S et al (2022) Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer : a randomized clinical trial. JAMA. View this article in WRRO
Lane JA, Donovan JL, Young GJ, Davis M, Walsh EI, Avery KNL, Blazeby JM, Mason MD, Martin RM, Peters TJ , Turner EL et al (2022) Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study). BJU International. View this article in WRRO
Klaassen Z, Catto JWF, Vickers AJ, Cooperberg MR & Kutikov A (2022) Reply to Benjamin Davies, Keith Kowalczyk RE: Zachary Klaassen, Emily Vertosick, Andrew J. Vickers, et al. Optimal Dissemination of Scientific Manuscripts via Social Media: A Prospective Trial Comparing Visual Abstracts Versus Key Figures in Consecutive Original Manuscripts. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.01.041. European Urology.
Hussain SA, Lester JF, Jackson R, Gornall M, Qureshi M, Elliott A, Crabb SJ, Huddart RA, Vasudev N, Birtle AJ , Worlding J et al (2022) Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE) : a double-blind, randomised, phase 2 trial. The Lancet Oncology, 23(5), 650-658. View this article in WRRO
Khetrapal P, Stafford R, Ó Scanaill P, Kocadag H, Timinis C, Chang AHL, Hadjivasiliou A, Liu Y, Gibbs O, Pickford E , Walker D et al (2022) Measuring patient compliance with remote monitoring following discharge from hospital after major surgery (DREAMPath): protocol for a prospective observational study. JMIR Research Protocols, 11(4).
Hussain SA, Qureshi M, Tahir B, Rehan A & Catto JWF (2022) Real-world evidence from a single U.K. cancer center for atezolizumab in second-line setting in advanced urothelial cancer: Moving beyond clinical trials.. Journal of Clinical Oncology, 40(6_suppl), 461-461.
McBride SM, Niazi T, Williams S, Davis ID, Stockler MR, Martin AJ, Bracken K, Roncolato FT, Horvath L, Sengupta S , Martin J et al (2022) DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. Journal of Clinical Oncology, 40(6_suppl), TPS284-TPS284.
Powles T, Drakaki A, Teoh JY-C, Grande E, Fontes-Sousa M, Porta C, Wu E, Goluboff ET, Ho S, Hois S , Gupta AK et al (2022) A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA).. Journal of Clinical Oncology, 40(6_suppl), TPS579-TPS579.
Catto JWF, Kelly JD, Khetrapal P, Ambler G, Ricciardi F, Khan S, Feber A, Dixon S, Williams N, Ahmed I , Charlesworth P et al (2022) Robot assisted radical cystectomy with intracorporeal urinary diversion versus open radical cystectomy: Results from the iROC prospective randomised controlled trial. European Urology, 81, S1125-S1125.
Kamat AM, Steinberg G, Inman B, Kates M, Uchio E, Porten S, Rouperet M, Palou J, Catto J, Kulkarni GS , Powles T et al (2022) Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC) (Trial in Progress). European Urology, 81, S507-S507.
Klaassen Z, Vertosick E, Vickers AJ, Assel MJ, Novara G, Pierce C, Wallis CJD, Larcher A, Cooperberg MR, Catto JWF & Kutikov A (2022) The optimal dissemination of scientific manuscripts via social media: A prospective randomized trial comparing visual abstracts with key figures using consecutive original manuscripts published in European Urology. European Urology, 81, S142-S143.
Klaassen Z, Vertosick E, Vickers AJ, Assel MJ, Novara G, Pierce C, Wallis CJD, Larcher A, Cooperberg MR, Catto JWF & Kutikov A (2022) Optimal Dissemination of Scientific Manuscripts via Social Media: A Prospective Trial Comparing Visual Abstracts Versus Key Figures in Consecutive Original Manuscripts Published in European Urology. European Urology.
Khadhouri S, Gallagher KM, MacKenzie KR, Shah TT, Gao C, Moore S, Zimmermann EF, Edison E, Jefferies M, Nambiar A , Anbarasan T et al (2022) Developing a Diagnostic Multivariable Prediction Model for Urinary Tract Cancer in Patients Referred with Haematuria: Results from the IDENTIFY Collaborative Study. European Urology Focus.
HITCHMAN L & MACHIN M (2022) Impact of COVID-19 on vascular patients worldwide: analysis of the COVIDSurg data. The Journal of Cardiovascular Surgery, 62(6).
Nepogodiev D, Simoes JFF, Li E, Picciochi M, Glasbey JC, Baiocchi G, Blanco‐Colino R, Chaudhry D, AlAmeer E, El‐Boghdadly K , Wuraola F et al (2022) SARS‐CoV‐2 infection and venous thromboembolism after surgery: an international prospective cohort study. Anaesthesia, 77(1), 28-39.
Galesloot TE, Grotenhuis AJ, Kolev D, Aben KK, Bryan RT, Catto JWF, Cheng KK, Conroy S, Dyrskjøt L, Fleshner NE , James ND et al (2022) Genome-wide meta-analysis identifies novel genes associated with recurrence and progression in non–muscle-invasive bladder cancer. European Urology Oncology, 5(1), 70-83.
(2021) Impact of Bacillus Calmette-Guérin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection. BJS Open, 5(6).
Tan WS, Leow JJ, Marchese M, Sridhar A, Hellawell G, Mossanen M, Teoh JYC, Fowler S, Colquhoun AJ, Cresswell J , Catto JWF et al (2021) Defining factors associated with high-quality surgery following radical cystectomy : analysis of the British Association of Urological Surgeons cystectomy audit. European Urology Open Science, 33, 1-10.
COVIDSurg Collaborative (2021) Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study.. Lancet Oncol.
Tamhankar AS, Thurtle D, Hampson A, El‐Taji O, Thurairaja R, Kelly JD, Catto JWF, Lane T, Adshead J & Vasdev N (2021) Radical cystectomy in England from 2013 to 2019 on 12,644 patients : an analysis of national trends and comparison of surgical approaches using Hospital Episode Statistics data. BJUI Compass, 2(5), 338-347.
Tan WS, Leow J, Marchese M, Sridhar A, Hellawell G, Mossanen M, Teoh J, Fowler S, Colquhoun A, Cresswell J , Catto J et al (2021) PD59-10 FACTORS ASSOCIATED WITH HIGH-QUALITY SURGERY FOLLOWING RADICAL CYSTECTOMY: ANALYSIS OF THE BRITISH ASSOCIATION OF UROLOGICAL SURGEONS (BAUS) CYSTECTOMY AUDIT. Journal of Urology, 206(Supplement 3).
Mariappan P, Ahmad I, Amer T, Andersen LD, Baker S, Bhatt J, Brown M, Bryan R, Catto JWF, Chahal R , Chapman A et al (2021) The Scottish Bladder Cancer Quality Performance Indicators Influencing Outcomes, Prognosis, and Surveillance (Scot BC Quality OPS) Clinical Project. European Urology Focus.
Van Poppel H, Roobol MJ, Chapple CR, Catto JWF, N’Dow J, Sønksen J, Stenzl A & Wirth M (2021) Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. European Urology.
Nepogodiev D, Simoes JFF, Li E, Picciochi M, Glasbey JC, Baiocchi G, Blanco‐Colino R, Chaudhry D, AlAmeer E, El‐Boghdadly K , Wuraola F et al (2021) Effects of pre‐operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study. Anaesthesia, 76(11), 1454-1464.
Psutka SP, Morgan T, Albersen M, Cornu J-N, Novara G, Plimack E, Ost P & Catto JWF (2021) The European Urology Commitment to Gender Equity and Diversity: Expanding Cognitive Diversity through Inclusivity at the Podium. European Urology.
Khetrapal P, Ó Scanaill P, Stafford R, Kocadag H, Chang A, Duncan J, Catto JWF, Lin P, Jin Li F, Walker D , Drobnjak I et al (2021) Using a remote monitoring kit to predict re-admissions for patients discharged following radical cystectomy. European Urology, 79, S1385-S1385.
Tan WS, Leow J, Marchese M, Sridhar A, Hellawell G, Mossanen M, Teoh J, Fowler S, Colquhoun A, Cresswell J , Catto J et al (2021) Defining factors associated with high-quality surgery following radical cystectomy: Analysis of the British Association of Urological Surgeons (BAUS) cystectomy audit. European Urology, 79, S1151-S1151.
Bryan RT, Catto JWF, Jefferson KP, Patel P, James ND & on behalf of the BladderPath Trial Management Group (2021) Reply to Trey Durdin, Alvin Goh, and Eugene Pietzak. Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.018. European Urology.
Briggs LG, Reitblat C, Bain PA, Parke S, Lam N-Y, Wright J, Catto JWF, Copeland RJ & Psutka SP (2021) Prehabilitation Exercise Before Urologic Cancer Surgery: A Systematic and Interdisciplinary Review. European Urology.
Akowuah E, Benson RA, Caruana EJ, Chetty G, Edwards J, Forlani S, Gradinariu G, Murphy GJ, Oo AY, Patel AJ , Ridley B et al (2021) Early outcomes and complications following cardiac surgery in patients testing positive for coronavirus disease 2019: An international cohort study. The Journal of Thoracic and Cardiovascular Surgery, 162(2), e355-e372.
(2021) SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study. British Journal of Surgery, 108(9), 1056-1063.
Nepogodiev D, Simoes JFF, Li E, Picciochi M, Glasbey JC, Baiocchi G, Blanco‐Colino R, Chaudhry D, AlAmeer E, El‐Boghdadly K , Wuraola F et al (2021) Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study. Anaesthesia, 76(6), 748-758.
Bryan RT, Liu W, Pirrie SJ, Amir R, Gallagher J, Hughes AI, Jefferson KP, Knight A, Nanton V, Mintz HP , Pope AM et al (2021) Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study. European Urology.
Powles T, Meeks JJ, Galsky MD, Van Der Heijden MS, Nishiyama H, Al-Ahmadie HA, Goluboff ET, Hois S, Donegan SE, Williams V , Xiao F et al (2021) A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA).. Journal of Clinical Oncology, 39(6_suppl), TPS505-TPS505.
Niazi T, Williams S, Davis ID, Stockler MR, Martin AJ, Bracken K, Roncolato F, Horvath L, Martin J, Lim TS , Hughes S et al (2021) DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. Journal of Clinical Oncology, 39(6_suppl), TPS266-TPS266.
Birtle AJ, Chester JD, Jones RJ, Jenkins B, Johnson M, Catto JWF, Powles T, Bryan RT, Blacker A, Chakraborti PR , Jagdev S et al (2021) Updated outcomes of POUT: A phase III randomized trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC).. Journal of Clinical Oncology, 39(6_suppl), 455-455.
Catto JWF, Downing A, Mason S, Wright P, Absolom K, Bottomley S, Hounsome L, Hussain S, Varughese M, Raw C , Kelly P et al (2021) Quality of life after bladder cancer: a cross-sectional survey of patient-reported outcomes. European Urology. View this article in WRRO
Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2021) Phase I trial of DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine for solid malignancies including urothelial carcinoma (SPIRE). Clinical Cancer Research. View this article in WRRO
Sutton E, Lane JA, Davis M, Walsh EI, Neal DE, Hamdy FC, Mason M, Staffurth J, Martin RM, Metcalfe C , Peters TJ et al (2021) Men’s experiences of radiotherapy treatment for localized prostate cancer and its long-term treatment side effects: a longitudinal qualitative study. Cancer Causes & Control, 32(3), 261-269.
Catto JWF, Gordon K, Collinson M, Poad H, Twiddy M, Johnson M, Jain S, Chahal R, Simms M, Dooldeniya M , Bell R et al (2020) Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-feasibility study. Journal of Clinical Oncology. View this article in WRRO
Panebianco V, Del Giudice F, Narumi Y, Simone G, De Berardinis E & Catto JWF (2020) Re: Helena Vila-Reyes, G. Joel DeCastro, and James M. McKiernan’s Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang’s Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636–43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.08.006. European Urology.
Gómez Rivas J, Rodríguez-Serrano A, Loeb S, Yuen-Chun Teoh J, Ribal MJ, Bloemberg J, Catto J, N’Dow J, van Poppel H, González J , Esteban M et al (2020) Telemedicine and smart working: Spanish adaptation of the European Association of Urology recommendations. Actas Urológicas Españolas (English Edition), 44(10), 644-652.
Reed O, Jubber I, Griffin J, Noon A, Goodwin L, Hussain S, Cumberbatch M & Catto J (2020) Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes. PLoS ONE, 15(10). View this article in WRRO
Del Giudice FD, Pecoraro M, Vargas HA, Cipollari S, De Berardinis E, Bicchetti M, Chung BI, Catalano C, Narumi Y, Catto JWF & Panebianco V (2020) Systematic review and meta-analysis of vesical imaging-reporting and data system (VI-RADS) inter-observer reliability : an added value for muscle invasive bladder cancer detection. Cancers, 12(10).
Woo S, Panebianco V, Narumi Y, Giudice FD, Muglia VF, Takeuchi M, Ghafoor S, Bochner BH, Goh AC, Hricak H , Catto JWF et al (2020) Corrigendum to ‘Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis’ [European Urology Oncology 3 (2020) 306-315]. European Urology Oncology, 3(6), 811-811.
Noble SM, Garfield K, Lane JA, Metcalfe C, Davis M, Walsh EI, Martin RM, Turner EL, Peters TJ, Thorn JC , Mason M et al (2020) The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. British Journal of Cancer, 123(7), 1063-1070.
Wallis CJD, Catto JWF, Finelli A, Glaser AW, Gore JL, Loeb S, Morgan TM, Morgans AK, Mottet N, Neal R , O’Brien T et al (2020) The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future. European Urology.
Wade J, Donovan J, Lane A, Davis M, Walsh E, Neal D, Turner E, Martin R, Metcalfe C, Peters T , Hamdy F et al (2020) Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial. BMJ Open, 10(9).
Gómez Rivas J, Rodríguez-Serrano A, Loeb S, Yuen-Chun Teoh J, Ribal MJ, Bloemberg J, Catto J, Dow JN, Van Poppel H, González J , Esteban M et al (2020) TELEMEDICINA Y TRABAJO INTELIGENTE: ADAPTACIÓN AL ESPAÑOL DE LAS RECOMENDACIONES DE LA ASOCIACIÓN EUROPEA DE UROLOGÍA. Actas Urológicas Españolas.
Niazi T, Williams S, Davis ID, Stockler MR, Martin A, Bracken K, Roncolato F, McJannett M, Horvath L, Sengupta S , Hughes S et al (2020) 694TiP DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. Annals of Oncology, 31, S548-S549.
Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Wade J, Noble S, Garfield K, Young G , Davis M et al (2020) Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer : the ProtecT three-arm RCT. Health Technology Assessment, 24(37), 1-175.
Ürün Y, Hussain SA, Bakouny Z, Castellano D, Kılıçkap S, Morgan G, Mckay RR, Pels K, Schmidt A, Doroshow DB , Schütz F et al (2020) Survey of the Impact of COVID-19 on Oncologists’ Decision Making in Cancer. JCO Global Oncology(6), 1248-1257.
Williams SB, Jubber I, Catto JWF & Daneshmand S (2020) Reply to Gianluca Giannarini, Vincenzo Ficarra, and Claudio Valotto’s Letter to the Editor re: Stephen B. Williams, Marcus G.K. Cumberbatch, Ashish M. Kamat, et al. Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.06.039. European Urology.
Mostafid H, Kamat AM, Daneshmand S, Palou J, Taylor JA, McKiernan J, Catto J, Babjuk M & Soloway M (2020) Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. European Urology Oncology.
Williams SB, Cumberbatch MGK, Kamat AM, Jubber I, Kerr PS, McGrath JS, Djaladat H, Collins JW, Packiam VT, Steinberg GD , Lee E et al (2020) Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. European Urology, 78(5), 719-730.
Neal DE, Metcalfe C, Donovan JL, Lane JA, Davis M, Young GJ, Dutton SJ, Walsh EI, Martin RM, Peters TJ , Turner EL et al (2020) Erratum to ‘Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received’ [European Urology 77 (2020) 320–330]. European Urology, 78(3), e139-e143.
Walz J, Bex A, Ploussard G, Proietti S & Catto J (2020) Open science and open publishing: A new paradigm for the European urology family. European Urology Open Science, 19, 1-2. View this article in WRRO
Khetrapal P, Catto JWF, Williams N, Ambler G, Sarpong R, Khan MS, Thurairaja R, Tan MEL, Feber A, Dixon S , Vasdev N et al (2020) Comparison of wearable device measured mobility with patient-reported mobility during peri-operative recovery following radical cystectomy. European Urology Open Science, 19, e1999-e1999.
Vasdev N, Tamhankar A, Adshead J, Catto J, Kelly J & Thurairaja R (2020) Radical cystectomy (open, laparoscopic and robotic) in 12625 patients in England: National trends and peri-operative outcomes from Hospital Episode Statistics data. European Urology Open Science, 19, e2281-e2282.
Williams S, Cumberbatch M, Kamat A, Kerr P, Mcgrath J, Djaladat H, Collins J, Jubber I, Packiam V, Steinberg G , Lee E et al (2020) Reporting radical cystectomy outcomes following implementation of Enhanced Recovery after Surgery (ERAS) protocols: A systematic review and individual patient data meta-analysis. European Urology Open Science, 19, e2280-e2280.
Galesloot T, Grotenhuis AJ, Fleshner NE, James ND, Bryan RT, Cheng KK, Zeegers MP, Mengual L, Catto JWF, Kolev D , Vermeulen SH et al (2020) Meta-analysis of six genome-wide association studies identifies novel loci associated with recurrence and progression of non-muscle invasive bladder cancer. European Urology Open Science, 19, e1369-e1369.
Bryan RT, Pirrie SJ, Liu W, Amir R, Gallagher J, Hughes AI, Jefferson KP, Knight A, Nanton V, Mintz HP , Pope AM et al (2020) Replacing TURBT with mpMRI for staging MIBC: Pilot data from the BladderPath trial. European Urology Open Science, 19, e824-e825.
Hassler MR, Bray F, Catto JWF, Grollman AP, Hartmann A, Margulis V, Matin SF, Roupret M, Sfakianos JP, Shariat SF & Faltas BM (2020) Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. European Urology, 78(2), 209-220.
Pang KH, Thomas F, Novara G, Din OS, Morgan SL, Hussain SA, Jubber I, Noon AP, Catto JWF & Rosario DJ (2020) The Impact of Centralised Services on Metric Reflecting High-quality Performance: Outcomes from 1110 Consecutive Radical Cystectomies at a Single Centre. European Urology Focus.
Cappuccini F, Bryant R, Pollock E, Carter L, Verrill C, Hollidge J, Poulton I, Baker M, Mitton C, Baines A , Meier A et al (2020) Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial. Journal for ImmunoTherapy of Cancer, 8(1), e000928-e000928.
Tuthill M, Cappuccini F, Bryant RJ, Poulton I, Pollock E, Carter L, Verrill C, Meier A, Schmidt G, Catto JWF , Evans T et al (2020) Phase I/II open label nonrandomized safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 immunotherapy in combination with PD-1 checkpoint blockade in intermediate-risk localized or locally advanced prostate cancer and advanced metastatic prostate cancer.. Journal of Clinical Oncology, 38(15_suppl), TPS3170-TPS3170.
Wallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, Morgan TM, Mottet N, Gillessen S, Bossi A , Roupret M et al (2020) Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. European Urology, 78(1), 29-42.
Khetrapal P, Conroy S, Kelly JD & Catto JWF (2020) Comparing open-radical cystectomy and robot-assisted radical cystectomy. Current Opinion in Urology, 30(3), 400-406.
Afferi L, Moschini M, Cumberbatch MG, Catto JW, Scarpa RM, Porpiglia F, Mattei A, Sanchez-Salas R & Esperto F (2020) Biomarkers predicting oncological outcomes of high-risk non-muscle-invasive bladder cancer. Minerva Urologica e Nefrologica, 72(3).
Stensland KD, Morgan TM, Moinzadeh A, Lee CT, Briganti A, Catto JWF & Canes D (2020) Considerations in the Triage of Urologic Surgeries During the COVID-19 Pandemic. European Urology, 77(6), 663-666.
Williams* S, Cumberbatch M, Kamat A, Kerr P, McGrath J, Djaladat H, Collins J, Jubber I, Packiam V, Steinberg G , Lee E et al (2020) PD51-11 REPORTING RADICAL CYSTECTOMY OUTCOMES FOLLOWING IMPLEMENTATION OF ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOLS. The Journal of Urology, 203, e1087-e1088.
Panebianco V, Del Giudice F, Leonardo C, Sciarra A, Catalano C & Catto JWF (2020) VI-RADS Scoring Criteria for Alternative Risk-adapted Strategies in the Management of Bladder Cancer During the COVID-19 Pandemic. European Urology, 78(1), e18-e20.
Pradère B, Ploussard G, Catto JWF, Rouprêt M & Misrai V (2020) The Use of Nonsteroidal Anti-inflammatory Drugs in Urological Practice in the COVID-19 Era: Is “Safe Better than Sorry”?. European Urology, 78(2), 134-135.
Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, Harris C, Winterbottom A, Blacker A, Catto JWF , Chakraborti P et al (2020) Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. The Lancet, 395(10232), 1268-1277. View this article in WRRO
Mostafid AH, Porta N, Cresswell J, Griffiths TRL, Kelly JD, Penegar SR, Davenport K, McGrath JS, Campain N, Cooke P , Masood S et al (2020) CALIBER - A phase II randomised feasibility trial of chemoablation with mitomycin versus surgical management in low risk non-muscle invasive bladder cancer. BJU International. View this article in WRRO
Mostafid H, Babjuk M, Bochner B, Lerner SP, Witjes F, Palou J, Roupret M, Shariat S, Gontero P, van Rhijn B , Zigeuner R et al (2020) Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. European Urology, 77(6), 669-670.
Woo S, Panebianco V, Narumi Y, Del Giudice F, Muglia VF, Takeuchi M, Ghafoor S, Bochner BH, Goh AC, Hricak H , Catto JWF et al (2020) Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. European Urology Oncology, 3(3), 306-315.
Khadhouri S, Gallagher KM, MacKenzie K, Shah TT, Gao C, Moore S, Zimmermann E, Edison E, Jefferies M, Nambiar A , MacLennan G et al (2020) IDENTIFY : The investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer: A multicentre cohort study. International Journal of Surgery Protocols, 21, 8-12. View this article in WRRO
James ND, Pirrie S, Liu W, Amir R, Gallagher J, Hughes A, Jefferson K, Knight A, Nanton V, Mintz HP , Pope A et al (2020) Replacing TURBT with mpMRI for staging MIBC: Pilot data from the BladderPath study.. Journal of Clinical Oncology, 38(6_suppl), 446-446.
Niazi T, Williams S, Davis ID, Stockler MR, Martin AJ, Hague W, Bracken K, Gorzeman M, Roncolato F, Yip S , Horvath L et al (2020) DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer.. Journal of Clinical Oncology, 38(6_suppl), TPS385-TPS385.
Steinberg GD, Palou-Redorta J, Gschwend JE, Tran B, Loriot Y, Daneshmand S, Roupret M, Santiago-Walker AE, Switzky JC, Major C , Baig M et al (2020) A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guérin (BCG) therapy.. Journal of Clinical Oncology, 38(6_suppl), TPS603-TPS603.
Del Giudice F, Catto JWF & Panebianco V (2020) Reply to Charalampos Fragkoulis, Georgios Papadopoulos, and Konstantinos Ntoumas’s Letter to the Editor re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and its Clinical Impact on the Management of High-risk Non–muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol 2020;77:101–9. European Urology, 77(4), e94-e95.
Bryant RJ, Oxley J, Young GJ, Lane JA, Metcalfe C, Davis M, Turner EL, Martin RM, Goepel JR, Varma M , Griffiths DF et al (2020) The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. BJU International, 125(4), 506-514.
Sathianathen NJ, Omer A, Harriss E, Davies L, Kasivisvanathan V, Punwani S, Moore CM, Kastner C, Barrett T, Van Den Bergh RCN , Eddy BA et al (2020) Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis. European Urology.
Rodriguez Socarrás M, Loeb S, Teoh JY-C, Ribal MJ, Bloemberg J, Catto J, N’Dow J, Van Poppel H & Gómez Rivas J (2020) Telemedicine and Smart Working: Recommendations of the European Association of Urology. European Urology.
Zwarthoff E & Hurst C (2020) Festschrift in Honor of Professor Margaret Anne Knowles. Bladder Cancer, 6(4), 537-548.
Jubber I, Shariat SF, Conroy S, Tan WS, Gordon PC, Lotan Y, Messing EM, Stenzl A, Rhijn BV, Kelly JD , Catto JWF et al (2020) Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis. European Urology, 77(5), 583-598.
Gontero P, Pisano F, Palou J, Joniau S, Albersen M, Colombo R, Briganti A, Pellucchi F, Faba OR, van Rhijn BW , van de Putte EF et al (2020) Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. World Journal of Urology, 38(8), 1959-1968.
Del Giudice F, Barchetti G, De Berardinis E, Pecoraro M, Salvo V, Simone G, Sciarra A, Leonardo C, Gallucci M, Catalano C , Catto JWF et al (2020) Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non–muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. European Urology, 77(1), 101-109.
Catto JWF (2020) Is Social Media Worth the Risk for Health Care Professionals?. European Urology Focus, 6(3), 427-429.
Moschini M, Shariat SF, Black P, Kamat AM, Stabile A, Cathelineau X, Kassouf W, Bochner BH, Xylinas E, Roupret M , Boorjian SA et al (2020) Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. European Urology, 77(1), 1-2.
Neal DE, Metcalfe C, Donovan JL, Lane JA, Davis M, Young GJ, Dutton SJ, Walsh EI, Martin RM, Peters TJ , Turner EL et al (2019) Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received. European Urology. View this article in WRRO
Lam TBL, MacLennan S, Willemse P-PM, Mason MD, Plass K, Shepherd R, Baanders R, Bangma CH, Bjartell A, Bossi A , Briers E et al (2019) EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). European Urology, 76(6), 790-813.
Leow JJ, Catto JWF, Efstathiou JA, Gore JL, Hussein AA, Shariat SF, Smith AB, Weizer AZ, Wirth M, Witjes JA & Trinh Q-D (2019) Quality indicators for bladder cancer services : a collaborative review. European Urology. View this article in WRRO
Shariat S, Gontero P & Catto JWF (2019) How to treat a patient with T1 high-grade disease and no tumour on repeat transurethral resection of the bladder?. European Urology Oncology. View this article in WRRO
(2019) Correction:Robot-assisted radical cystectomy with intracorporeal urinary diversion versus open radical cystectomy (iROC): protocol for a randomised controlled trial with internal feasibility study. BMJ Open, 9(8), e020500corr1-e020500corr1.
Ray-Zack M, Cerantola Y, Kerr P, Rodriguez LH, Collins J, Douglas J, Djaladat H, Fairchild L, Mayson K, Smith J , Johansen A et al (2019) Outcomes of radical cystectomy following implementation of enhanced recovery after surgery protocols: A systematic review. Clinical Nutrition ESPEN, 31, 142-142.
Mason SJ, Downing A, Wright P, Bottomley SE, Winterbottom A, Glaser AW & Catto JWF (2019) Life and bladder cancer: protocol for a longitudinal and cross-sectional patient-reported outcomes study of Yorkshire (UK) patients. BMJ Open, 9(6), e030850-e030850.
Donovan JL, Opmeer B, Young GJ, Mills N, Martin RM, Lane JA, Metcalfe C, Peters TJ, Davis M, Turner EL , Walsh E et al (2019) Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study. Journal of Clinical Epidemiology, 113, 200-213.
Grimm M-O, Bex A, De Santis M, Ljungberg B, Catto JWF, Rouprêt M, Hussain SA, Bellmunt J, Powles T, Wirth M & Van Poppel H (2019) Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. European Urology, 76(3), 368-380.
Powles T, Meeks JJ, Galsky MD, Van Der Heijden MS, Nishiyama H, Al-Ahmadie H, Gupta AK, Ye J, Donegan SE, Ghiorghiu DC , Ferro S et al (2019) A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA).. Journal of Clinical Oncology, 37(15_suppl), TPS4592-TPS4592.
Williams SB & Catto JWF (2019) Reply from Authors re: Peter Albers. Volume Matters: Can We Rely on the Evidence? Eur Urol Oncol 2019;2:274–5. European Urology Oncology, 2(3), 276-276.
Gandaglia G, Albers P, Abrahamsson P-A, Briganti A, Catto JWF, Chapple CR, Montorsi F, Mottet N, Roobol MJ, Sønksen J , Wirth M et al (2019) Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. European Urology, 76(2), 142-150.
Donnelly DW, Gavin A, Downing A, Hounsome L, Kearney T, McNair E, Allan D, Huws DW, Wright P, Selby PJ , Kind P et al (2019) Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom. European Urology, 76(2), 228-237.
Sathianathen* N, Omer A, Moore C, Kasivisvanathan V, van den Bergh R, Punwani S, Kastner C, Barrett T, Murphy D, Catto J , MacPherson R et al (2019) MP24-19 NEGATIVE PREDICTIVE VALUE OF MULTI-PARAMETRIC MRI IN DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS. Journal of Urology, 201(Supplement 4).
Panebianco V, Narumi Y, Barchetti G, Montironi R & Catto JWF (2019) Should We Perform Multiparametric Magnetic Resonance Imaging of the Bladder Before Transurethral Resection of Bladder? Time to Reconsider the Rules. European Urology, 76(1), 57-58.
Wymer* K, Sharma V, Borah B, Catto J, Thompson RH, Karnes RJ & Boorjian S (2019) MP29-12 COMPARATIVE COST-EFFECTIVENESS OF ACTIVE SURVEILLANCE, RADICAL PROSTATECTOMY, AND EXTERNAL BEAM RADIOTHERAPY: LESSONS FROM PROTECT. Journal of Urology, 201(Supplement 4).
Pang KH, Novara GH, Din OS, Morgan SL, Noon AP, Catto JWF & Rosario DJ (2019) Long term survival after radical cystectomy with respect to centralisation: Outcomes from 1110 patients treated at a single high-volume centre. European Urology Supplements, 18(1), e1134-e1134.
Mostafid H, Porta N, Cresswell J, Griffiths T, Kelly J, Catto J, Davenport K, McGrath J, Cooke P, Masood S , Feber A et al (2019) 12 month results of CALIBER: A phase II randomised feasibility trial of chemoablation with MMC versus surgical management in low risk (LR) non-muscle invasive bladder cancer (NMIBC). European Urology Supplements, 18(1), e762-e763.
Borgmann H, Cooperberg MR, Murphy D, Loeb S, N’Dow J, Ribal MJ, Woo H, Rouprêt M, Winterbottom A, Wijburg CJ , Wirth M et al (2019) Online professionalism - 2018 update of European Association of Urology (@Uroweb) commendations on the appropriate use of social media. European Urology Supplements, 18(1), e2147-e2148.
Khetrapal P, Williams NR, Ambler G, Sarpong R, Khan MS, Tan MEL, Feber A, Dixon S, Vasdev N, Goodwin L , McGrath J et al (2019) The iROC trial: An RCT comparing intracorporeal robot-assisted vs open radical cystectomy for bladder cancer. European Urology Supplements, 18(1), e1844-e1844.
Murali-Krishnan S, Pang KH, Greco F, Fiori C, Catto JW, Vavassori VL & Esperto F (2019) Bladder-sparing treatment in MIBC: where do we stand?. Minerva Urologica e Nefrologica, 71(2).
Barchetti G, Simone G, Ceravolo I, Salvo V, Campa R, Del Giudice F, De Berardinis E, Buccilli D, Catalano C, Gallucci M , Catto JWF et al (2019) Multiparametric MRI of the bladder: inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center. European Radiology, 29(10), 5498-5506.
McNeill RV, Mason AS, Hodson ME, Catto JWF & Southgate J (2019) Specificity of the metallothionein-1 response by cadmium-exposed normal human urothelial cells. International Journal of Molecular Sciences, 20(6). View this article in WRRO
Downing A, Wright P, Hounsome L, Selby P, Wilding S, Watson E, Wagland R, Kind P, Donnelly DW, Butcher H , Catto JWF et al (2019) Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study. The Lancet Oncology, 20(3), 436-447. View this article in WRRO
Khetrapal P, Catto JWF & Kelly JD (2019) Robot-assisted versus open cystectomy in the RAZOR trial. The Lancet, 393(10172), 644-645.
Stubendorff B, Wilhelm K, Posselt K, Catto J, Hartmann A, Bertz S, Füssel S, Novotny V, Toma M, Gajda M , Lehmann J et al (2019) A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer. Journal of Cancer Research and Clinical Oncology, 145(4), 811-820.
Butcher G, Howard H, Sathianathen N, Catto JWF & Murphy DG (2019) Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer. European Urology, 76(6), 872-873.
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang T-H, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA , Ziv E et al (2019) The Immune Landscape of Cancer. Immunity, 51(2), 411-412.
Palou J, Brausi M & Catto JWF (2019) Management of Patients with Normal Cystoscopy but Positive Cytology or Urine Markers. European Urology Oncology.
Jubber I, Pang KH, Groves R, Reed O, Noon AP, Catto JWF & Cumberbatch MG (2019) Impact of Anaesthetist Volume on Radical Cystectomy Outcomes. European Urology Focus.
Assel M, Sjoberg DD, Catto JWF & Vickers AJ (2019) Innovations in Statistical Review at European Urology. European Urology, 75(1), 1-2.
Panebianco V, Barentsz J, Narumi Y & Catto JWF (2019) Reply to Jeremy Y.C. Teoh, Thomas R.W. Herrmann, and Marek Babjuk's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018;74:294–306. European Urology, 75(2), e29-e30.
Williams SB, Ray-Zack MD, Hudgins HK, Oldenburg J, Trinh Q-D, Nguyen PL, Shore ND, Wirth MP, O’Brien T & Catto JWF (2019) Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review. European Urology Oncology, 2(3), 265-273.
Khetrapal P, Kelly JD, Catto JWF & Vasdev N (2019) Does the robot have a role in radical cystectomy?. BJU International, 123(3), 380-382.
Bancroft EK, Saya S, Page EC, Myhill K, Thomas S, Pope J, Chamberlain A, Hart R, Glover W, Cook J , Rosario DJ et al (2019) Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations. BJU International, 123(2), 284-292.
Gordon PC, Thomas F, Noon AP, Rosario DJ & Catto JWF (2019) Long-term Outcomes from Re-resection for High-risk Non–muscle-invasive Bladder Cancer: A Potential to Rationalize Use. European Urology Focus, 5(4), 650-657.
Peng X, Chen Z, Farshidfar F, Xu X, Lorenzi PL, Wang Y, Cheng F, Tan L, Mojumdar K, Du D , Ge Z et al (2018) Molecular characterization and clinical relevance of metabolic expression subtypes in human cancers. Cell Reports, 23(1), 255-269.e4. View this article in WRRO
Marcq G, Voskuilen C, eiler R, Rink M, Poyet C, Noon A, Roghmann F, Necchi A, Aziz A, Young M , Marks P et al (2018) Carcinome urothélial au sein d’un diverticule de vessie : étude multicentrique des caractéristiques cliniques, anatomopathologiques et des résultats oncologiques. Progrès en Urologie, 28(13), 718-718.
Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK-S, Jeong KJ, Tsang YH, Moreno D, Bhavana VH , Peng X et al (2018) Comprehensive molecular characterization of the hippo signaling pathway in cancer. Cell Reports, 25(5), 1304-1317.e5. View this article in WRRO
Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G , Kwong LN et al (2018) A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. Cell Systems, 7(4), 422-437.e7.
Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, Kiemeney L, Lotan Y, Pang K, Silverman DT , Znaor A et al (2018) Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. European Urology. View this article in WRRO
Psutka SP, Barocas DA, Catto JWF, Gore JL, Lee CT, Morgan TM, Master VA, Necchi A, Rouprêt M & Boorjian SA (2018) Staging the Host: Personalizing Risk Assessment for Radical Cystectomy Patients. European Urology Oncology, 1(4), 292-304.
Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, Huddart R, Kennish S, Lerner S, Montironi R , Muglia VF et al (2018) Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). European Urology, 74(3), 294-306. View this article in WRRO
Kahles A, Lehmann K-V, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, Stegle O, Kohlbacher O, Sander C, Rätsch G , Caesar-Johnson SJ et al (2018) Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell, 34(2), 211-224.e6.
Catto JWF, Khetrapal P, Ambler G, Sarpong R, Khan MS, Tan M, Feber A, Dixon S, Goodwin L, Williams NR , McGrath J et al (2018) Robot-assisted radical cystectomy with intracorporeal urinary diversion versus open radical cystectomy (iROC): protocol for a randomised controlled trial with internal feasibility study. BMJ Open, 8(8), e020500-e020500. View this article in WRRO
Panebianco V, Barentsz J, Narumi Y & Catto J (2018) Reply to Andrea Necchi, Antonella Messina, and Alberto Briganti's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018;74:294–306. European Urology, 74(5), e109-e109.
Melling GE, Flannery SE, Abidin SA, Clemmens H, Prajapati P, Hinsley EE, Hunt S, Catto JWF, Coletta RD, Mellone M , Thomas GJ et al (2018) Corrigendum: A miRNA-145/TGF-β1 negative feedback loop regulates the cancer-associated fibroblast phenotype. Carcinogenesis, 39(8), 1094-1094.
Jepson M, Elliott D, Conefrey C, Wade J, Rooshenas L, Wilson C, Beard D, Blazeby JM, Birtle A, Halliday A , Stein R et al (2018) An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. Journal of Clinical Epidemiology, 99, 75-83.
Briganti A, Fossati N, Catto JWF, Cornford P, Montorsi F, Mottet N, Wirth M & Van Poppel H (2018) Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. European Urology, 74(3), 357-368.
Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R , Bottaro DP et al (2018) The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 23(12), 3698-3698.
Elliott D, Hamdy FC, Leslie TA, Rosario D, Dudderidge T, Hindley R, Emberton M, Brewster S, Sooriakumaran P, Catto JWF , Emara A et al (2018) Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer. BJU International, 122(6), 970-977.
Pang KH, Groves R & Catto JWF (2018) Reply to Mark C. Kendall's Letter to the Editor re: Karl H. Pang, Ruth Groves, Suresh Venugopal, Aidan P. Noon, James W.F. Catto. Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy. Eur Urol 2018;73:363–71. European Urology, 74(3), e66-e66.
Cumberbatch MGK, Foerster B, Catto JWF, Kamat AM, Kassouf W, Jubber I, Shariat SF, Sylvester RJ & Gontero P (2018) Repeat Transurethral Resection in Non–muscle-invasive Bladder Cancer: A Systematic Review [Figure presented]. European Urology, 73(6), 925-933. View this article in WRRO
Melling G, Flannery S, Abidin S, Clemmens H, Prajapati P, Hinsley E, Hunt S, Catto J, Della Coletta R, Mellone M , Thomas G et al (2018) A miRNA-145/TGF-β1 negative feedback loop regulates the cancer-associated fibroblast phenotype. Carcinogenesis, 39(6), 798-807. View this article in WRRO
Catto JWF, Khetrapal P, Ambler G, Sarpong R, Potyka I, Khan MS, Tan M, Feber A, Bourke L, Noon AP , Dixon S et al (2018) Multidomain Quantitative Recovery Following Radical Cystectomy for Patients Within the Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion Versus Open Radical Cystectomy Randomised Controlled Trial: The First 30 Patients. European Urology, 74(4), 531-534.
Redchenko I, Cappuccini F, Pollock E, Bryant RJ, Carter L, Verrill C, Hollidge J, Goodwin L, Harrop R, Romero PJ , Vigano S et al (2018) VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer.. Journal of Clinical Oncology, 36(15_suppl), 3018-3018.
Newton RU, Kenfield SA, Hart NH, Chan JM, Courneya KS, Catto J, Finn SP, Greenwood R, Hughes DC, Mucci L , Plymate SR et al (2018) Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. BMJ Open, 8(5), e022899-e022899.
Mason SJ, Downing A, Wright P, Hounsome L, Bottomley SE, Corner J, Richards M, Catto JW & Glaser AW (2018) Health-related quality of life after treatment for bladder cancer in England. British Journal of Cancer. View this article in WRRO
Mason SJ, Catto JWF, Downing A, Bottomley SE, Glaser AW & Wright P (2018) Evaluating patient-reported outcome measures (PROMs) for bladder cancer: a systematic review using the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) checklist. BJU International. View this article in WRRO
Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J , Lazar AJ et al (2018) Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell, 33(4), 676-689.e3.
Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V , Rao A et al (2018) A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell, 33(4), 690-705.e9.
Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, Seoane JA, Farshidfar F, Bowlby R, Islam M , Kim J et al (2018) Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell, 33(4), 721-735.e8.
Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, Jia L, Li S, Xie W, Yang D , Caesar-Johnson SJ et al (2018) lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell, 33(4), 706-720.e9.
Huang K-L, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N , Scott AD et al (2018) Pathogenic Germline Variants in 10,389 Adult Cancers. Cell, 173(2), 355-370.e14.
Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, Gibbs DL, Weerasinghe A, Huang K-L, Tokheim C , Cortés-Ciriano I et al (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell, 173(2), 305-320.e10.
Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B , Ng PK-S et al (2018) Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell, 173(2), 371-385.e18.
Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V , Akbani R et al (2018) Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell, 173(2), 291-304.e6.
Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV , Omberg L et al (2018) An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, 173(2), 400-416.e11.
Chen H, Li C, Peng X, Zhou Z, Weinstein JN, Liang H, Caesar-Johnson SJ, Demchok JA, Felau I, Kasapi M , Ferguson ML et al (2018) A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell, 173(2), 386-399.e12.
Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S , Chakravarty D et al (2018) Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell, 173(2), 321-337.e10.
Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kamińska B, Huelsken J, Omberg L, Gevaert O , Colaprico A et al (2018) Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell, 173(2), 338-354.e15.
Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, Smith PG, Buonamici S, Yu L, Caesar-Johnson SJ , Demchok JA et al (2018) Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell Reports, 23(1), 282-296.e4.
Jayasinghe RG, Cao S, Gao Q, Wendl MC, Vo NS, Reynolds SM, Zhao Y, Climente-González H, Chai S, Wang F , Varghese R et al (2018) Systematic Analysis of Splice-Site-Creating Mutations in Cancer. Cell Reports, 23(1), 270-281.e3. View this article in WRRO
Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS , Liu Y et al (2018) Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Reports, 23(1), 239-254.e6.
Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, Samaras D, Shroyer KR, Zhao T, Batiste R , Van Arnam J et al (2018) Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Reports, 23(1), 181-193.e7.
Gao Q, Liang W-W, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, Liao W-W, Reynolds SM, Wyczalkowski MA, Yao L , Yu L et al (2018) Driver fusions and their implications in the development and treatment of human cancers. Cell Reports, 23(1), 227-238.e3. View this article in WRRO
Chiu H-S, Somvanshi S, Patel E, Chen T-W, Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS, Sood AK , Gunaratne PH et al (2018) Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell Reports, 23(1), 297-312.e12.
Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R , Bottaro DP et al (2018) The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 23(1), 313-326.e5.
Crabb S, Danson SJ, Catto JWF, McDowell C, Lowder JN, Caddy J, Dunkley D, Rajaram J, Ellis D, Hill S , Hathorn D et al (2018) SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: Study protocol for a phase Ib/randomised IIa open label clinical trial. Trials, 19(1). View this article in WRRO
Birtle A, Catto J, Johnson M, Kockelbergh R, Keeley F, Bryan R, Chester J, Jones R, Hill M, Donovan J , French A et al (2018) MP18-03 RESULTS OF POUT - A PHASE III RANDOMISED TRIAL OF PERI-OPERATIVE CHEMOTHERAPY VERSUS SURVEILLANCE IN UPPER TRACT UROTHELIAL CANCER (UTUC). Journal of Urology, 199(4S).
Voskuilen C, Seiler R, Rink M, Poyet C, Noon A, Roghmann F, Necchi A, Aziz A, Lavollé A, Young M , Marks P et al (2018) MP41-14 UROTHELIAL CARCINOMA IN BLADDER DIVERTICULA: A MULTICENTER ANALYSIS OF CHARACTERISTICS AND TREATMENT OUTCOME. Journal of Urology, 199(4S).
Mostafid H, Malde S, Mir-Kohler A, Bagnall P, Taylor J, Cresswell J & Catto J (2018) MP08-08 DISCHARGE OF LOW RISK NON MUSCLE INVASIVE BLADDER CANCER AFTER ONE YEAR: RESULTS OF A BAUS/BAUN NATIONAL SURVEY OF THE ADOPTION OF THE NICE BLADDER CANCER GUIDELINES RECOMMENDATIONS IN THE UK. Journal of Urology, 199(4S).
Mostafid H, Cresswell J, Griffiths L, Kelly J, Knight A, Catto J, Davenport K, Feber A, Knowles M, McGrath J , Cooke P et al (2018) PD66-04 RESULTS OF CALIBER: A PHASE II RANDOMISED FEASIBILITY TRIAL OF CHEMOABLATION VERSUS SURGICAL MANAGEMENT IN LOW RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC). Journal of Urology, 199(4S).
Khetrapal P, Williams N, Tan M, Feber A, Ambler G, Sarpong R, Khan S, Dixon S, Goodwin L, McGrath J , Rowe E et al (2018) MP71-18 THE USE OF FITNESS TRACKER IN MONITORING FUNCTIONAL ACTIVITY OF PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR BLADDER CANCER: A FEASIBILITY REPORT AND ANALYSIS AS PART OF THE MULTI-CENTRE RANDOMISED IROC TRIAL. Journal of Urology, 199(4S). View this article in WRRO
Donovan JL, Young GJ, Walsh EI, Metcalfe C, Lane JA, Martin RM, Tazewell MK, Davis M, Peters TJ, Turner EL , Mills N et al (2018) A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. Journal of Clinical Epidemiology, 96, 35-46.
Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, Hess J, Ma S, Chiotti KE, McLellan M , Sofia HJ et al (2018) Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Systems, 6(3), 271-281.e7.
Donnelly DW, Donnelly C, Kearney T, Weller D, Sharp L, Downing A, Wilding S, Wright P, Kind P, Catto JWF , Cross WR et al (2018) Urinary, bowel and sexual health in older men from Northern Ireland. BJU International. View this article in WRRO
Martin RM, Donovan JL, Turner EL, Metcalfe C, Young GJ, Walsh EI, Lane JA, Noble S, Oliver SE, Evans S , Sterne JAC et al (2018) Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality. JAMA, 319(9), 883-883.
Pisano F, Gontero P, Filippini C, Karnes J, Colicchia M, Colombo R, Joniau S, Milenkovic U, Albersen M, Minervini A , Mari A et al (2018) Disease and patient’s characteristics in elderly (≥75 years) treated with radical cystectomy: results of a large multicentre retrospective series. European Urology Supplements, 17(2), e1024-e1025.
Mostafid H, Malde S, Mir-Kohler A, Bagnall P, Taylor J, Cresswell J & Catto J (2018) Discharge of low risk non muscle invasive bladder cancer after one year: Results of a national survey of the adoption of the NICE bladder cancer guidelines recommendations in the UK. European Urology Supplements, 17(2), e1068-e1068.
Voskuilen C, Seiler R, Rink M, Poyet C, Noon A, Roghmann F, Necchi A, Aziz A, Lavollé A, Young M , Marks P et al (2018) Urothelial carcinoma in bladder diverticula: A multicenter analysis of characteristics and treatment outcome in 110 patients. European Urology Supplements, 17(2), e532-e533.
Mostafid H, Cresswell J, Griffiths T, Kelly J, Knight A, Catto J, Davenport K, Feber A, Knowles M, McGrath J , Cooke P et al (2018) Results of CALIBER: A phase II randomised feasibility trial of chemoablation versus surgical management in low risk non-muscle invasive bladder cancer. European Urology Supplements, 17(2), e1062-e1063.
Birtle A, Johnson M, Kockelbergh R, Keeley F, Catto J, Bryan R, Chester J, Jones R, Hill M, Donovan J , French A et al (2018) Results of POUT - a phase III randomised trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). European Urology Supplements, 17(2), e1431-e1432.
Wallis CJD & Klaassen Z (2018) Response to Claire Vale, David Fisher, Jayne Tierney, Ian White, Matthew Sydes, and James Carpenter's Letter to the Editor re: Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.10.002. European Urology, 73(3), e51-e51.
Pang KH, Groves R, Venugopal S, Noon AP & Catto JWF (2018) Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy. European Urology, 73(3), 363-371. View this article in WRRO
Thiruchelvam N, Joyce A, Speakman M, Catto JWF, Hagan P, Fowler S, Hermans L & Keeley F (2018) Improving Standards of Care through the Publication of Surgeon Identifiable Outcome Data in Urology. European Urology, 74(1), 1-3.
Penegar S, Lewis R, Catto J, Cresswell J, Griffiths L, Hill M, Kelly J, Knight A, McGrath J, Wiley L , Mostafid H et al (2018) Correction to: Meeting abstracts from the 4th International Clinical Trials Methodology Conference (ICTMC) and the 38th Annual Meeting of the Society for Clinical Trials. Trials, 19(1).
Borgmann H, Cooperberg M, Murphy D, Loeb S, N’Dow J, Ribal MJ, Woo H, Rouprêt M, Winterbottom A, Wijburg C , Wirth M et al (2018) Online Professionalism—2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. European Urology, 74(5), 644-650.
Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B , Kwok-Shing Ng P et al (2018) Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell, 174(4), 1034-1035.
Klaassen Z, Kamat AM, Kassouf W, Gontero P, Villavicencio H, Bellmunt J, van Rhijn BWG, Hartmann A, Catto JWF & Kulkarni GS (2018) Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. European Urology, 74(5), 597-608.
Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R , Byers LA et al (2018) Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports, 23(1), 194-212.e6.
Ge Z, Leighton JS, Wang Y, Peng X, Chen Z, Chen H, Sun Y, Yao F, Li J, Zhang H , Liu J et al (2018) Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. Cell Reports, 23(1), 213-226.e3.
Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, Sander C, Cherniack AD, Mina M, Ciriello G , Schultz N et al (2018) Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Cell Reports, 23(1), 172-180.e3.
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang T-H, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA , Ziv E et al (2018) The Immune Landscape of Cancer. Immunity, 48(4), 812-830.e14.
Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, Zhao W, Zhang X, Ventura A, Liu Y , Ayer DE et al (2018) Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Systems, 6(3), 282-300.e2.
Cumberbatch MG & Catto JWF (2018) Re: Comprehensive Molecular Characterization of Muscle Invasive Bladder Cancer. European Urology, 73(3), 479-480. View this article in WRRO
Kamat AM, Li R, O’Donnell MA, Black PC, Roupret M, Catto JW, Comperat E, Ingersoll MA, Witjes WP, McConkey DJ & Witjes JA (2018) Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. European Urology, 73(5), 738-748.
Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R , Castro MAA et al (2017) Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell, 171(3), 540-556.e25.
Obajemu O, Mahfouf M & Catto JWF (2017) A New Fuzzy Modeling Framework for Integrated Risk Prognosis and Therapy of Bladder Cancer Patients. IEEE Transactions on Fuzzy Systems, 26(3), 155-1577. View this article in WRRO
Oughton JB, Poad H, Twiddy M, Collinson M, Hiley V, Gordon K, Johnson M, Jain S, Noon AP, Chahal R , Simms M et al (2017) Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): A protocol for a randomised controlled feasibility study. BMJ Open, 7(8). View this article in WRRO
Catto JWF (2017) Speeding up recovery from radical cystectomy: how low can we go?. BJU International, 120(2), 162-163. View this article in WRRO
MacLennan SJ, MacLennan S, Bex A, Catto JWF, De Santis M, Glaser AW, Ljungberg B, N’Dow J, Plass K, Trapero-Bertran M , Van Poppel H et al (2017) Changing current practice in urology: Improving guideline development and implementation through stakeholder engagement. European Urology, 72(2), 161-163. View this article in WRRO
Bourke L, Bauld L, Bullen C, Cumberbatch M, Giovannucci E, Islami F, McRobbie H, Silverman DT & Catto JWF (2017) E-cigarettes and Urologic Health: A Collaborative Review of Toxicology, Epidemiology, and Potential Risks. European Urology, 71(6), 915-923.
MacLennan S, Williamson PR, Bekema H, Campbell M, Ramsay C, N'Dow J, MacLennan S, Vale L, Dahm P, Mottet N & Lam T (2017) A core outcome set for localised prostate cancer effectiveness trials. BJU International.
Pang KH, Rosario DJ, Morgan SL & Catto JWF (2017) Evaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role for future cancer using non-malignant prostate biopsies. PLOS ONE, 12(4). View this article in WRRO
Leslie T, Elliott D, Le Conte S, Brewster S, Sooriakumaran P, Bryant R, Dudderidge T, Rosario D, Catto J, Hindley R , Emberton M et al (2017) A phase III study comparing partial prostate ablation versus radical prostatectomy (PART) in intermediate risk prostate cancer – initial data from the feasibility study. European Urology Supplements, 16(3), e1316-e1318.
Pang K, Groves R, Noon A & Catto J (2017) The application of ERAS pathways to radical cystectomy: Outcomes from 482 consecutive cases. European Urology Supplements, 16(3), e1023-e1023.
Borgmann H, Katz M, Catto J, Weight C & Kutikov A (2017) What is #urology tweeting about? Strategic assessment of Twitter communication in urology. European Urology Supplements, 16(3), e1440-e1442.
Johnston TJ, Shaw GL, Lamb AD, Parashar D, Greenberg D, Xiong T, Edwards AL, Gnanapragasam V, Holding P, Herbert P , Davis M et al (2017) Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. European Urology. View this article in WRRO
Mandalapu RS, Remzi M, de Reijke TM, Margulis V, Palou J, Kapoor A, Yossepowitch O, Coleman J, Traxer O, Anderson JK , Catto J et al (2017) Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. World Journal of Urology, 35(3), 355-365. View this article in WRRO
Autorino R, Porpiglia F, Dasgupta P, Rassweiler J, Catto JW, Hampton LJ, Lima E, Mirone V, Derweesh IH & Debruyne FMJ (2017) Precision surgery and genitourinary cancers. European Journal of Surgical Oncology (EJSO). View this article in WRRO
Edmondson AJ, Birtwistle JC, Catto JWF & Twiddy M (2017) The patients’ experience of a bladder cancer diagnosis: a systematic review of the qualitative evidence. Journal of Cancer Survivorship. View this article in WRRO
Panebianco V, De Berardinis E, Barchetti G, Simone G, Leonardo C, Grompone MD, Del Monte M, Carano D, Gallucci M, Catto J & Catalano C (2017) An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer. European Radiology.
Dal Moro F, Haber GP, Wiklund P, Canda AE, Balbay MD, Stenzl A, Zattoni F, Palou J, Gill I & Catto JWF (2017) Robotic intracorporeal urinary diversion: Practical review of current surgical techniques. Minerva Urologica e Nefrologica, 69(1), 14-25.
Catto JWF, Blazeby JM, Holmberg L, Hamdy FC & Brown J (2017) In Defense of Randomized Clinical Trials in Surgery: Let Us Not Forget Archie Cochrane's Legacy. European Urology. View this article in WRRO
Borgmann H, Katz MS, Catto J, Weight C & Kutikov A (2017) Quantification of Urology Related Twitter Traffic Activity through a Standardized List of Social Media Communication Descriptors. Urology Practice, 4(4), 349-354.
Klatte T, Giannarini G, Briganti A & Catto JW (2016) Kidney Cancer: Many Important Advances but Still a Lot to Debate. European Urology Focus, 2(6), 565-566.
Zietman A, Smith J, Klein E, Droller M, Dasgupta P & Catto J (2016) In Reply to Samaratunga et al. International Journal of Radiation Oncology*Biology*Physics, 96(5), 1127-1128.
Downing A, Wright P, Wagland R, Watson E, Kearney T, Mottram R, Allen M, Cairnduff V, McSorley O, Butcher H , Hounsome L et al (2016) Life after prostate cancer diagnosis: protocol for a UK-wide patient-reported outcomes study. BMJ Open, 6(12). View this article in WRRO
Cumberbatch MG & Catto JW (2016) The Use of Biomarkers to Manage Men with Metastatic Prostate Cancer: One Day, But Not Yet. European Urology Focus, 2(5), 467-468.
(2016) Reply to letter to editor about new Gleason grading system: Statement from the editors of six journals. Urologic Oncology: Seminars and Original Investigations, 34(11), 481-481.
Patterson K, Arya L, Bottomley S, Morgan S, Cox A, Catto J & Bryant HE (2016) Altered RECQL5 expression in urothelial bladder carcinoma increases cellular proliferation and makes RECQL5 helicase activity a novel target for chemotherapy.. Oncotarget. View this article in WRRO
Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM , Oxley J et al (2016) 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. New England Journal of Medicine, 375(15), 1415-1424. View this article in WRRO
Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, Blazeby JM, Peters TJ, Holding P, Bonnington S , Lennon T et al (2016) Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. New England Journal of Medicine, 375(15), 1425-1437. View this article in WRRO
Zietman A, Klein E, Droller MJ, Dasgupta P, Catto J & Jr SJA (2016) Consensus Guidelines for Reporting Prostate Cancer Gleason Grade Reply. JOURNAL OF UROLOGY, 196(4), 1322-1323.
Giannarini G, Klatte T, Catto JW & Briganti A (2016) Beware of Bugs! Hot Issues in Urinary Tract Infections and Inflammation. European Urology Focus, 2(4), 339-340.
Gandaglia G, Briganti A, Fossati N, Salonia A, Mottrie A, Catto J & Montorsi F (2016) The Problem Is Not What to Do with Indolent and Harmless Prostate Cancer—The Problem Is How to Avoid Finding These Cancers. European Urology, 70(4), 547-548.
Cumberbatch MG, Rota M, Catto JWF & La Vecchia C (2016) Reply to Wentao Liu, Xiaokun Zhao, Zhaohui Zhong's Letter to the Editor re: Marcus G. Cumberbatch, Matteo Rota, James W.F. Catto, Carlo La Vecchia. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. Eur Urol 2016;70:458–66. European Urology, 70(4), e106-e107.
Collins JW, Patel H, Adding C, Annerstedt M, Dasgupta P, Khan S, Artibani W, Gaston R, Piechaud T, Catto JW , Koupparis A et al (2016) Enhanced recovery after robot-assisted radical cystectomy: EAU Robotic Urology Section (ERUS) scientific working group consensus statement view. European Urology Supplements, 15(7), 225-225.
Zietman A, Smith J, Klein E, Droller M, Dasgupta P & Catto J (2016) Consensus guidelines for reporting prostate cancer Gleason Grade Reply. BJU INTERNATIONAL, 118(3), E2-E2.
Mason MD, Moore R, Jones G, Lewis G, Donovan JL, Neal DE, Hamdy FC, Lane JA & Staffurth JN (2016) Radiotherapy for Prostate Cancer: is it ‘what you do’ or ‘the way that you do it’? A UK Perspective on Technique and Quality Assurance. Clinical Oncology, 28(9), e92-e100.
Cumberbatch MG, Rota M, Catto JWF & La Vecchia C (2016) The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. European Urology, 70(3), 458-466. View this article in WRRO
Lane A, Metcalfe C, Young GJ, Peters TJ, Blazeby J, Avery KNL, Dedman D, Down L, Mason MD, Neal DE , Hamdy FC et al (2016) Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life. BJU International. View this article in WRRO
Egevad L, Samaratunga H, Srigley JR, Delahunt B, Zietman A, Smith J, Klein E, Droller M, Dasgupta P & Catto J (2016) Consensus guidelines for reporting prostate cancer Gleason Grade. BJU International, 118(3), E1-E2.
Cumberbatch MG, Windsor-Shellard B & Catto JWF (2016) The contemporary landscape of occupational bladder cancer within the United Kingdom: a meta-analysis of risks over the last 80 years. BJU International. View this article in WRRO
Zietman A, Smith J, Klein E, Droller M, Dasgupta P & Catto J (2016) Reply to Lars Egevad, Hemamali Samaratunga, John R. Srigley, Brett Delahunt's Letter to the Editor re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. Eur Urol 2016;70:1. European Urology.
Noon AP, Martinsen JI, Catto JWF & Pukkala E (2016) Occupation and Bladder Cancer Phenotype: Identification of Workplace Patterns That Increase the Risk of Advanced Disease Beyond Overall Incidence. European Urology Focus.
Klein EA, Smith JA, Zietman AL, Dasgupta P, Catto J, Droller M & Millar S (2016) Re: Samaratunga et al: Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. Urology.
Klatte T, Giannarini G, Catto JW & Briganti A (2016) Urinary Incontinence: Moving the Field Forward. European Urology Focus, 2(3), 229-230.
Zietman A, Klein E, Droller MJ, Dasgupta P, Catto J & Jr SJA (2016) CONSENSUS GUIDELINES FOR REPORTING PROSTATE CANCER GLEASON GRADE. JOURNAL OF UROLOGY, 195(6), 1723-1723.
Fossati N, Giannarini G, Klatte T, Catto JW & Briganti A (2016) The Rapidly Evolving Role of Imaging in Urology: How to Balance Breakthroughs in Knowledge with Overuse. European Urology Focus, 2(2), 111-112.
Panebianco V, Barchetti F, de Haas RJ, Pearson RA, Kennish SJ, Giannarini G & Catto JWF (2016) Improving Staging in Bladder Cancer: The Increasing Role of Multiparametric Magnetic Resonance Imaging. European Urology Focus, 2(2), 113-121.
Collins JW, Patel H, Adding C, Annerstedt M, Dasgupta P, Khan SM, Artibani W, Gaston R, Piechaud T, Catto JW , Koupparis A et al (2016) Enhanced Recovery After Robot-assisted Radical Cystectomy: EAU Robotic Urology Section Scientific Working Group Consensus View. European Urology, 70(4), 649-660.
Zietman A, Smith J, Klein E, Droller M, Dasgupta P & Catto J (2016) Consensus guidelines for reporting prostate cancer Gleason Grade. BJU International, 117(6), 849-849.
Zietman A, Smith J, Klein E, Droller MJ, Dasgupta P & Catto J (2016) New Gleason grading system: Statement from the Editors of six journals. Urologic Oncology: Seminars and Original Investigations, 34(6), 253-253.
Cumberbatch MG & Catto JWF (2016) Micropapillary Variant Bladder Cancer: A Bad Apple or a New Fruit?. European Urology.
Saunders EJ, Dadaev T, Leongamornlert DA, Olama AAA, Benlloch S, Giles GG, Wiklund F, Grönberg H, Haiman CA, Schleutker J , Nordestgaard BG et al (2016) Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. British Journal of Cancer, 114(8), 945-952.
Giannarini G, Briganti A, Klatte T, Shariat SF & Catto JW (2016) Reducing Complications After Surgery: Still a Long Way To Go. European Urology Focus, 2(1), 1-2.
Moschini M, Simone G, Stenzl A, Gill IS & Catto J (2016) Critical Review of Outcomes from Radical Cystectomy: Can Complications from Radical Cystectomy Be Reduced by Surgical Volume and Robotic Surgery?. European Urology Focus, 2(1), 19-29.
Bourke L, Smith D, Steed L, Hooper R, Carter A, Catto J, Albertsen PC, Tombal B, Payne HA & Rosario DJ (2016) Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 69(4), 693-703.
Zietman A, Smith J, Klein E, Droller M, Dasgupta P & Catto J (2016) Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. Urology, 93, 1-1.
Zietman A, Smith J, Klein E, Droller M, Dasgupta P & Catto J (2016) Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. European Urology, 70(1), 1-1.
Smith JA, Zietman A, Klein E, Droller MJ, Dasgupta P, Catto J & Smith JA (2016) Stage Grouping. The Journal of Urology, 195(6), 1723-1723.
Azhar RA, Bochner B, Catto J, Goh AC, Kelly J, Patel HD, Pruthi RS, Thalmann GN & Desai M (2016) Enhanced Recovery after Urological Surgery: A Contemporary Systematic Review of Outcomes, Key Elements, and Research Needs. European Urology, 70(1), 176-187.
Zietman AL, Smith J, Klein E, Droller M, Dasgupta P & Catto J (2016) Editorial Statement on Gleason Scoring for Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics, 95(4), 1092-1092.
Moschini M, Briganti A, Murphy CR, Bianchi M, Gandaglia G, Montorsi F, Quevedo JF, Carlson R, Kwon E & Karnes RJ (2016) Outcomes for Patients with Clinical Lymphadenopathy Treated with Radical Prostatectomy. European Urology, 69(2), 193-196.
Klatte T, Shariat SF, Briganti A, Giannarini G & Catto JW (2016) Adrenal Lesions: Progress on All Fronts. European Urology Focus, 1(3), 215-216.
Kutikov A, Woo HH & Catto JW (2016) Urology Tag Ontology Project: Standardizing Social Media Communication Descriptors. European Urology, 69(2), 183-185.
Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Epstein JI, Cascinu S, Briganti A, Catto JW, Montorsi F & Montironi R (2016) Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. European Urology, 69(2), 186-190. View this article in WRRO
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR & Humphrey PA (2015) The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. The American Journal of Surgical Pathology, 1-1.
(2015) Error in Data. JAMA Oncology, 1(9), 1224-1224.
Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, Bonnetain F, Bossi A, Bracarda S , Bukowski R et al (2015) Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. Annals of Oncology, 26(12), 2392-2398.
Cumberbatch MGK, Cox A, Teare D & Catto JWF (2015) Contemporary Occupational Carcinogen Exposure and Bladder Cancer. JAMA Oncology, 1(9), 1282-1290. View this article in WRRO
Wade J, Holding PN, Bonnington S, Rooshenas L, Lane JA, Salter CE, Tilling K, Speakman MJ, Brewster SF, Evans S , Neal DE et al (2015) Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial. BMJ Open, 5(9). View this article in WRRO
Briganti A, Giannarini G, Klatte T, Catto JW & Shariat SF (2015) The Future of Prostate Cancer Diagnosis: Biomarkers, Biopsy, Both, or Neither?. European Urology Focus, 1(2), 97-98.
Blick C, Ramachandran A, McCormick R, Wigfield S, Cranston D, Catto J & Harris AL (2015) Identification of a hypoxia-regulated miRNA signature in bladder cancer and a role for miR-145 in hypoxia-dependent apoptosis. British Journal of Cancer, 113(4), 634-644. View this article in WRRO
Kluth LA, Black PC, Bochner BH, Catto J, Lerner SP, Stenzl A, Sylvester R, Vickers AJ, Xylinas E & Shariat SF (2015) Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. European Urology, 68(2), 238-253.
Amin Al Olama A, Benlloch S, Antoniou AC, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Muir K, Schleutker J , Henderson BE et al (2015) Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiology Biomarkers & Prevention, 24(7), 1121-1129. View this article in WRRO
Wang W-T, Catto JWF & Meuth M (2015) Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors. Oncogene, 34(22), 2887-2896. View this article in WRRO
Laird A, Fowler S, Good DW, Stewart GD, Srinivasan V, Cahill D, Brewster SF & McNeill SA (2015) Contemporary practice and technique-related outcomes for radical prostatectomy in the UK: a report of national outcomes. BJU International, 115(5), 753-763.
El-Shater Bosaily A, Parker C, Brown LC, Gabe R, Hindley RG, Kaplan R, Emberton M & Ahmed HU (2015) PROMIS — Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer. Contemporary Clinical Trials, 42, 26-40.
Boström PJ, Bjartell AS, Catto JWF, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T & Cooperberg MR (2015) Genomic Predictors of Outcome in Prostate Cancer. European Urology, 68(6), 1033-1044. View this article in WRRO
Stubendorff B, Wilhelm K, Posselt K, Catto J, Schaeffeler E, Schwaab M, Füssel S, Novotny V, Hartmann A, Gajda M , Wunderlich H et al (2015) 747 Identification of specific methylation-based biomarkers for the assessment of the metastatic risk of muscle invasive bladder cancer. European Urology Supplements, 14(2), e747-e747.
Peter S, Borkowska E, Drayton R, Rakhit C, Noon A, Chen W & Catto J (2015) 232 Identification of differentially expressed long non-coding RNAs in bladder cancer. European Urology Supplements, 14(2), e232-e232.
Pang KH, Cumberbatch MG, Wilson SA & Catto JWF (2015) 527 N6-methyladenosine mRNA methylation in common human cancers: Identifying a potential role in androgen-resistance within prostate cancer. European Urology Supplements, 14(2), e527-e527a.
Cumberbatch MGK, Viphakone N, Livingstone M, Heath PR, Dickman M, Catto JWF & Wilson SA (2015) 227 Luzp4 defines a new mRNA export pathway in cancer cells. European Urology Supplements, 14(2), e227-e227b.
Pang KH, Miah S, Drayton RM, Rehman I, Clarke R, Stoehr R, Hartmann A, Lavin M, Bryant HE, Martens-Uzunova ES , Jenster G et al (2015) 426 Identification and diagnostic performance of a small RNA within the PCA3 and BMCC1 gene locus that potentially targets mRNA. European Urology Supplements, 14(2), e426-e426b.
Loeb S, Montorsi F & Catto JW (2015) Future-proofing Gleason Grading: What to Call Gleason 6 Prostate Cancer?. European Urology, 68(1), 1-2. View this article in WRRO
Wilson TG, Guru K, Rosen RC, Wiklund P, Annerstedt M, Bochner BH, Chan KG, Montorsi F, Mottrie A, Murphy D , Novara G et al (2015) Best Practices in Robot-assisted Radical Cystectomy and Urinary Reconstruction: Recommendations of the Pasadena Consensus Panel. European Urology, 67(3), 363-375.
Chan KG, Guru K, Wiklund P, Catto J, Yuh B, Novara G, Murphy DG, Al-Tartir T, Collins JW, Zhumkhawala A & Wilson TG (2015) Robot-assisted Radical Cystectomy and Urinary Diversion: Technical Recommendations from the Pasadena Consensus Panel. European Urology, 67(3), 423-431.
Martin NE, Massey L, Stowell C, Bangma C, Briganti A, Bill-Axelson A, Blute M, Catto J, Chen RC, D’Amico AV , Feick G et al (2015) Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. European Urology, 67(3), 460-467.
Viphakone N, Cumberbatch MG, Livingstone MJ, Heath PR, Dickman MJ, Catto JW & Wilson SA (2015) Luzp4 defines a new mRNA export pathway in cancer cells. Nucleic Acids Research, 43(4), 2353-2366. View this article in WRRO
De Alejandro Montalvo J, Panoutsos G, Mahfouf M & Catto JW (2015) High Dimensionality and Scaling-up Performance of RBF Models with Application to Healthcare Informatics. International Journal of Machine Learning and Computing, 5(1), 62-67.
Yuh B, Wilson T, Bochner B, Chan K, Palou J, Stenzl A, Montorsi F, Thalmann G, Guru K, Catto JWF , Wiklund PN et al (2015) Systematic Review and Cumulative Analysis of Oncologic and Functional Outcomes After Robot-assisted Radical Cystectomy. European Urology, 67(3), 402-422. View this article in WRRO
Novara G, Catto JWF, Wilson T, Annerstedt M, Chan K, Murphy DG, Motttrie A, Peabody JO, Skinner EC, Wiklund PN , Guru KA et al (2015) Systematic Review and Cumulative Analysis of Perioperative Outcomes and Complications After Robot-assisted Radical Cystectomy. European Urology, 67(3), 376-401. View this article in WRRO
Catto JL, Jakob C & Nicholls N (2015) Can the CMIP5 models represent winter frontal precipitation?. Geophysical Research Letters, 42(20), 8596-8604.
Catto JL, Madonna E, Joos H, Rudeva I & Simmonds I (2015) Global Relationship between Fronts and Warm Conveyor Belts and the Impact on Extreme Precipitation*. Journal of Climate, 28(21), 8411-8429.
Amin Al Olama A, Dadaev T, Hazelett DJ, Li Q, Leongamornlert D, Saunders EJ, Stephens S, Cieza-Borrella C, Whitmore I, Benlloch Garcia S , Giles GG et al (2015) Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Human Molecular Genetics, 24(19), 5589-5602.
Shariat SF, Catto JW, Klatte T, Giannarini G & Briganti A (2015) There Are Cooler Ways to Die Than Smoking: Urologists of the World, Unite Against This Health Care Tragedy. European Urology Focus, 1(1), 1-2.
Bryan RT, Evans T, Dunn JA, Iqbal G, Bathers S, Collins SI, James ND, Catto JWF & Wallace DMA (2015) A Comparative Analysis of the Influence of Gender, Pathway Delays, and Risk Factor Exposures on the Long-term Outcomes of Bladder Cancer. European Urology Focus, 1(1), 82-89. View this article in WRRO
Casey RG, Catto JWF, Cheng L, Cookson MS, Herr H, Shariat S, Witjes JA & Black PC (2015) Diagnosis and Management of Urothelial Carcinoma In Situ of the Lower Urinary Tract: A Systematic Review. European Urology, 67(5), 876-888. View this article in WRRO
Drayton RM, Rehman I, Clarke R, Zhao Z, Pang K, Miah S, Stoehr R, Hartmann A, Blizard S, Lavin M , Bryant HE et al (2015) Identification and Diagnostic Performance of a Small RNA within the PCA3 and BMCC1 Gene Locus That Potentially Targets mRNA. Cancer Epidemiology Biomarkers & Prevention, 24(1), 268-275. View this article in WRRO
Catto JWF, Cooperberg MR, Cornu J-N, Gratzke C, Novara G, Shariat SF & Vickers A (2015) European Urology: Serving Our Readership Through Systematic Peer Review, Use of Reporting Standards, and Encouragement of Postpublication Review. European Urology, 67(2), 188-190.
Gerlinger M, Catto JW, Orntoft TF, Real FX, Zwarthoff EC & Swanton C (2014) Intratumour Heterogeneity in Urologic Cancers: From Molecular Evidence to Clinical Implications. European Urology. View this article in WRRO
Catto JL, Nicholls N, Jakob C & Shelton KL (2014) Atmospheric fronts in current and future climates. Geophysical Research Letters, 41(21), 7642-7650.
Borkowska EM, Kruk A, Jedrzejczyk A, Rozniecki M, Jablonowski Z, Traczyk M, Constantinou M, Banaszkiewicz M, Pietrusinski M, Sosnowski M , Hamdy FC et al (2014) Molecular subtyping of bladder cancer using Kohonen self-organizing maps. Cancer Medicine, 3(5), 1225-1234. View this article in WRRO
van Rhijn BWG, Catto JW, Goebell PJ, Knüchel R, Shariat SF, van der Poel HG, Sanchez-Carbayo M, Thalmann GN, Schmitz-Dräger BJ & Kiemeney LA (2014) Molecular markers for urothelial bladder cancer prognosis: Toward implementation in clinical practice. Urologic Oncology: Seminars and Original Investigations, 32(7), 1078-1087.
Catto JWF, Montorsi F & Schulman C (2014) In Memory of John Fitzpatrick. European Urology, 66(3), 604-604.
Noon AP & Catto JWF (2014) Noncoding RNA in bladder cancer. Current Opinion in Urology, 24(5), 506-511.
Peter S, Borkowska E, Drayton RM, Rakhit CP, Noon A, Chen W & Catto JW (2014) Identification of Differentially Expressed Long Noncoding RNAs in Bladder Cancer. Clinical Cancer Research, 20(20), 5311-5321.
Drayton RM, Peter S, Myers K, Miah S, Dudziec E, Bryant HE & Catto JWF (2014) MicroRNA-99a and 100 mediated upregulation of FOXA1 in bladder cancer. Oncotarget, 5(15), 6375-6386. View this article in WRRO
Govekar PD, Jakob C & Catto J (2014) The relationship between clouds and dynamics in Southern Hemisphere extratropical cyclones in the real world and a climate model. Journal of Geophysical Research: Atmospheres, 119(11), 6609-6628.
Cazier J-B, Rao SR, McLean CM, Walker AK, Wright BJ, Jaeger EEM, Kartsonaki C, Marsden L, Yau C, Camps C , Kaisaki P et al (2014) Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden.. Nat Commun, 5, 3756. View this article in WRRO
Borkowska EM, Kruk A, Jedrzejczyk A, Rozniecki M, Jablonowski Z, Traczyk M, Constantinou M, Banaszkiewicz M, Pietrusinski M, Sosnowski M , Hamdy FC et al (2014) 995 Kohonen's self-organizing map for molecular subtyping in bladder cancer. European Urology Supplements, 13(1), e995-e995.
Pang K, Nicholas JWJ, Miah S, Wickramarachchi R, Venugopal S & Catto JW (2014) 326 It's a cover-up: The history of foreskin restoration. European Urology Supplements, 13(1), e326-e326.
Stubendorff B, Wilhelm K, Posselt K, Catto J, Hartmann A, Füssel S, Gajda M, Wunderlich H, Grimm M-O & Junker K (2014) 43 Promoter hypermethylation of KISS1R, KiSS1, SEPT9 and CSAD as a prognostic biomarker panel to assess the metastatic potential of muscle invasive bladder tumors. European Urology Supplements, 13(1), e43-e43.
Miah S & Catto J (2014) BPH and prostate cancer risk. Indian Journal of Urology, 30(2), 214-214.
Drayton RM, Dudziec E, Peter S, Bertz S, Hartmann A, Bryant HE & Catto JW (2014) Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.. Clinical Cancer Research, 20(7), 1990-2000. View this article in WRRO
Miah S, Pang K & Catto JWF (2014) MicroRNA and urothelial cell carcinoma.. BJU Int, 113(5), 811-812.
Martínez-Alvarado O, Gray SL, Catto JL & Clark PA (2014) Corrigendum: Sting jets in intense winter North-Atlantic windstorms (2012 Environ. Res. Lett. 7 024014). Environmental Research Letters, 9(3), 039501-039501.
Hope P, Keay K, Pook M, Catto J, Simmonds I, Mills G, McIntosh P, Risbey J & Berry G (2014) A Comparison of Automated Methods of Front Recognition for Climate Studies: A Case Study in Southwest Western Australia. Monthly Weather Review, 142(1), 343-363.
Loeb S, Catto J & Kutikov A (2014) Social Media Offers Unprecedented Opportunities for Vibrant Exchange of Professional Ideas Across Continents. European Urology, 66(1), 118-119.
Lane JA, Donovan JL, Davis M, Walsh E, Dedman D, Down L, Turner EL, Mason MD, Metcalfe C, Peters TJ , Martin RM et al (2014) Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. The Lancet Oncology, 15(10), 1109-1118.
Cazier J-B, Rao SR, McLean CM, Walker AK, Wright BJ, Jaeger EEM, Kartsonaki C, Marsden L, Yau C, Camps C , Kaisaki P et al (2014) Erratum: Corrigendum: Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden. Nature Communications, 5(1).
Liu Y, Noon AP, Aguiar Cabeza E, Shen J, Kuk C, Ilczynski C, Ni R, Sukhu B, Chan K, Barbosa-Morais NL , Hermanns T et al (2014) Next-generation RNA Sequencing of Archival Formalin-fixed Paraffin-embedded Urothelial Bladder Cancer. European Urology, 66(6), 982-986.
Rouprêt M, Morgan TM, Bostrom PJ, Cooperberg MR, Kutikov A, Linton KD, Palou J, Martínez-Piñeiro L, van der Poel H, Wijburg C , Winterbottom A et al (2014) European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. European Urology, 66(4), 628-632.
Cazier JB, Rao SR, McLean CM, Walker AL, Wright BJ, Jaeger EE, Kartsonaki C, Marsden L, Yau C, Camps C , Kaisaki P et al (2014) Corrigendum: Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden.. Nat Commun, 5, 4264.
Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K , Mæhle L et al (2014) Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology, 66(3), 489-499.
Patel HRH, Cerantola Y, Valerio M, Persson B, Jichlinski P, Ljungqvist O, Hubner M, Kassouf W, Müller S, Baldini G , Carli F et al (2014) Enhanced recovery after surgery: are we ready, and can we afford not to implement these pathways for patients undergoing radical cystectomy?. Eur Urol, 65(2), 263-266.
Ploussard G & Catto JW (2014) The quest for an optimal definition of prostate-specific antigen failure following radical prostatectomy: the risk of not seeing the forest for the trees.. Eur Urol, 66(2), 211-213.
Catto J (2013) Correspondence. The Library, 14(4), 465-466.
Gan C, Patel A, Fowler S, Catto J, Rosario D & O′Brien T (2013) Snapshot of Transurethral resection of bladder tumours in the United Kingdom Audit (STUKA). BJU International, n/a-n/a.
Wang W-T, Catto J & Meuth M (2013) Abstract B61: Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors.. Cell Cycle Regulators.
Catto JL & Pfahl S (2013) The importance of fronts for extreme precipitation. Journal of Geophysical Research: Atmospheres, 118(19), 10,791-10,801.
Jolly S, Howson J, Catto J, Haynes M, Cutinha P, Yates D & Rosario D (2013) Clinical microsystems in designing TRUS-biopsy services – A closed-loop audit of a specialist nurse-led triage clinic for men with suspected prostate cancer. International Journal of Surgery, 11(8), 727-727.
Borkowska EM, Kruk A, Jedrzejczyk A, Rozniecki M, Jablonowski Z, Traczyk M, Constantinou M, Banaszkiewicz M, Pietrusinski M, Sosnowski M , Hamdy FC et al (2013) C105 Molecular subtyping of bladder cancer using Kohonen self-organizing maps. European Urology Supplements, 12(4), e1213, C105-e1213, C105.
Catto JB, Bianchin I, Feijó GLD, Araújo FR, Ramos CADN & Castelão ABC (2013) Weight gain and control of endo- and ectoparasites of beef heifers treated with allopathic, herbal and homeopathic drugs. Revista Brasileira de Parasitologia Veterinária, 22(4), 502-510.
Fragkopoulou C, Munbauhal G, Webber S, Reynolds SM, Groves R, Cutinha PE, Catto JWF, Haynes MD, Yates DR, Buck J & Rosario DJ (2013) Predicting immediate level of care requirement following radical cystectomy – Audit of outcome. International Journal of Surgery, 11(8), 724-724.
Pang KH & Catto JWF (2013) Bladder cancer. Surgery (United Kingdom), 31(10), 523-529.
Linton KD & Catto JWF (2013) Prostate cancer. Surgery (United Kingdom), 31(10), 516-522.
Heidenreich A, Abrahamsson P-A, Artibani W, Catto J, Montorsi F, Van Poppel H, Wirth M & Mottet N (2013) Early Detection of Prostate Cancer: European Association of Urology Recommendation. European Urology, 64(3), 347-354.
Blick C, Ramachandran A, Wigfield S, McCormick R, Jubb A, Buffa FM, Turley H, Knowles MA, Cranston D, Catto J & Harris AL (2013) Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer. British Journal of Cancer, 109(1), 50-59. View this article in WRRO
Barbieri CE, Bangma CH, Bjartell A, Catto JWF, Culig Z, Grönberg H, Luo J, Visakorpi T & Rubin MA (2013) The mutational landscape of prostate cancer.. Eur Urol, 64(4), 567-576.
Noon AP, Albertsen PC, Thomas F, Rosario DJ & Catto JWF (2013) Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients.. Br J Cancer, 108(7), 1534-1540. View this article in WRRO
Birtle A, Lewis R, Chester J, Donovan J, Johnson M, Jones R, Kockelbergh R, Powles T, Bryan R, Catto J , Jones E et al (2013) 81 Peri-operative chemotherapy or surveillance in upper tract urothelial cancer (POUT – CRUK/11/027) – a randomised controlled trial to define standard post-operative management. European Urology Supplements, 12(1), e81-e82.
Patel A, Catto J, Rosario D, Gan C & O'Brien TS (2013) 568 Snapshot of transurethral resection of new bladder tumours in the UK Audit – STUKA. European Urology Supplements, 12(1), e568-e569.
Stubendorff B, Wilhelm K, Dubey S, Dudziec E, Catto JWF, Gajda M, Grimm M-O & Junker K (2013) 56 Specific changes in the DNA methylation pattern enable an early assessment of the metastatic risk of primary bladder tumours. European Urology Supplements, 12(1), e56-e56.
Skeldon SC, Semotiuk K, Aronson M, Holter S, Gallinger S, Pollett A, Kuk C, van Rhijn B, Bostrom P, Cohen Z , Fleshner NE et al (2013) Patients with Lynch Syndrome Mismatch Repair Gene Mutations Are at Higher Risk for Not Only Upper Tract Urothelial Cancer but Also Bladder Cancer. European Urology, 63(2), 379-385.
Noon AP & Catto JWF (2013) Bladder cancer in 2012: Challenging current paradigms. Nature Reviews Urology.
Larré S, Catto JWF, Cookson MS, Messing EM, Shariat SF, Soloway MS, Svatek RS, Lotan Y, Zlotta AR & Grossman HB (2013) Screening for bladder cancer: rationale, limitations, whom to target, and perspectives.. Eur Urol, 63(6), 1049-1058.
Linton KD & Catto JWF (2013) Upper tract urothelial carcinoma. Journal of Clinical Urology, 6(5), 272-279.
Catto JWF, Montorsi F & Schulman C (2013) European Urology: Quality, Impact, Online. European Urology.
Bourke L, Hooper R, Steed LA, Joshi M, Gilbert S, Saxton JM, Catto JWF & Rosario DJ (2013) Lifestyle Changes for Improving Disease-specific Quality of Life in Sedentary Men on Long-term Androgen-Deprivation Therapy for Advanced Prostate Cancer: A Randomised Controlled Trial. European Urology.
Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, Rosario DJ, Scattoni V & Lotan Y (2013) Systematic Review of Complications of Prostate Biopsy. European Urology, 64(6), 876-892.
Rink M, Babjuk M, Catto JWF, Jichlinski P, Shariat SF, Stenzl A, Stepp H, Zaak D & Witjes JA (2013) Hexyl Aminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-up of Patients with Non-Muscle-invasive Bladder Cancer: A Critical Review of the Current Literature. European Urology.
Borkowska EM, Jedrzejczyk A, Marks P, Catto JWF & Kałuzewski B (2013) EORTC risk tables - Their usefulness in the assessment of recurrence and progression risk in non-muscle-invasive bladder cancer in Polish patients. Central European Journal of Urology, 66(1), 14-20.
Catto JWF & Shariat SF (2013) The changing face of renal cell carcinoma: the impact of systematic genetic sequencing on our understanding of this tumor's biology.. Eur Urol, 63(5), 855-857.
Linton KD, Rosario DJ, Thomas F, Rubin N, Goepel JR, Abbod MF & Catto JWF (2013) Disease specific mortality in patients with low risk bladder cancer and the impact of cystoscopic surveillance.. J Urol, 189(3), 828-833.
Yates DR & Catto JWF (2013) Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours.. World J Urol, 31(1), 21-29.
Thomas F, Noon AP, Rubin N, Goepel JR & Catto JWF (2013) Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer.. Eur Urol, 63(1), 145-154.
Burger M, Catto JWF, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S & Lotan Y (2013) Epidemiology and risk factors of urothelial bladder cancer.. Eur Urol, 63(2), 234-241.
Yates DR, Brausi MA, Catto JWF, Dalbagni G, Rouprêt M, Shariat SF, Sylvester RJ, Witjes JA, Zlotta AR & Palou-Redorta J (2012) Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.. Eur Urol, 62(6), 1088-1096.
Cumberbatch M, Cox A, Catto J & Pickvance S (2012) Contemporary Occupational Bladder Cancer: A Systematic Review and Meta-Analysis of Recently Reported Exposures that Increase Risk. UROLOGY, 80(3), S1-S2.
Catto JL, Nicholls N & Jakob C (2012) North Australian Sea Surface Temperatures and the El Niño–Southern Oscillation in the CMIP5 Models. Journal of Climate, 25(18), 6375-6382.
Atkins CD & Wrzesinski SH (2012) Radiotherapy plus chemotherapy in muscle-invasive bladder cancer.. N Engl J Med, 367(4), 380.
(2012) Radiotherapy plus Chemotherapy in Muscle-Invasive Bladder Cancer. New England Journal of Medicine, 367(4), 379-381.
Catto JL, Nicholls N & Jakob C (2012) North Australian Sea Surface Temperatures and the El Niño–Southern Oscillation in Observations and Models. Journal of Climate, 25(14), 5011-5029.
Ziegler MA, Catto JA, Riggs TW, Gates ER, Grodsky MB & Wasvary HJ (2012) Risk Factors for Anastomotic Leak and Mortality in Diabetic Patients Undergoing Colectomy. Archives of Surgery, 147(7).
Miah S, Dudziec E, Drayton RM, Zlotta AR, Morgan SL, Rosario DJ, Hamdy FC & Catto JWF (2012) An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer.. Br J Cancer, 107(1), 123-128. View this article in WRRO
Thomas F, Rosario DJ, Rubin N, Goepel JR, Abbod MF & Catto JWF (2012) The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: time to change treatment paradigm?. Cancer, 118(22), 5525-5534.
Stubendorff B, Dudziec E, Catto J, Sanjmyatav J, Gaida M, Wunderlich H, Grimm M-O & Junker K (2012) Abstract 5014: Differences in DNA methylation pattern of primary bladder tumours correlate with their metastatic potential. Molecular and Cellular Biology.
Linton KD & Catto JWF (2012) Whole-body magnetic resonance imaging and prostate cancer metastases: a new gold standard of detection, but does it help us and at what cost?. Eur Urol, 62(1), 76-77.
Dudziec E, Gogol-Döring A, Cookson V, Chen W & Catto J (2012) Integrated Epigenome Profiling of Repressive Histone Modifications, DNA Methylation and Gene Expression in Normal and Malignant Urothelial Cells. PLoS ONE, 7(3). View this article in WRRO
Miah S & Catto JWF (2012) MicroRNA in prostate cancer: an opportunity to individualize patient care.. J Urol, 187(4), 1155-1156.
Cumberbatch M, Catto J & Pickvance S (2012) Contemporary occupational bladder cancer: A systematic review of current exposures. International Journal of Surgery, 10(8), S96-S96.
Bryant RJ, Pawlowski T, Catto JWF, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T & Hamdy FC (2012) 435 Circulating microRNAs are associated with the development and progression of prostate cancer. European Urology Supplements, 11(1), e435-e435a.
Linton KD, Rosario DJ, Thomas F, Rubin N, Abbod MF & Catto JWF (2012) 1043 Routine cystoscopic surveillance is ineffective in preventing death due to bladder cancer in patients with low risk disease. European Urology Supplements, 11(1), e1043-e1043a.
Stubendorff B, Dudziec E, Catto JWF, Sanjmyatav J, Gajda M, Wunderlich H, Grimm MO & Junker K (2012) 166 Differences in DNA methylation pattern of primary bladder tumours correlate with their metastatic potential. European Urology Supplements, 11(1), e166-e166.
Thomas F, Rubin N, Goepel J, Abbod MF, Rosario D & Catto JWF (2012) 965 The long term outcome of high risk non-muscle invasive bladder cancer. European Urology Supplements, 11(1), e965-e965a.
Stubendorff B, Dudziec E, Catto JWF, Sanjmyatav J, Gajda M, Wunderlich H, Grimm MO & Junker K (2012) Differences in DNA methylation pattern of primary bladder tumours correlate with their metastatic potential. EUROPEAN UROLOGY SUPPLEMENTS, 11(1), E166-E166.
Bryant RJ, Pawlowski T, Catto JWF, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T & Hamdy FC (2012) Circulating microRNAs are associated with the development and progression of prostate cancer. EUROPEAN UROLOGY SUPPLEMENTS, 11(1), E435-U952.
Thomas F, Rubin N, Goepel J, Abbod MF, Rosario D & Catto JWF (2012) The long term outcome of high risk non-muscle invasive bladder cancer. EUROPEAN UROLOGY SUPPLEMENTS, 11(1), E965-EU26.
Linton KD, Rosario DJ, Thomas F, Rubin N, Abbod MF & Catto JWF (2012) Routine cystoscopic surveillance is ineffective in preventing death due to bladder cancer in patients with low risk disease. EUROPEAN UROLOGY SUPPLEMENTS, 11(1), E1043-EU179.
Drayton RM & Catto JWF (2012) Molecular mechanisms of cisplatin resistance in bladder cancer.. Expert Rev Anticancer Ther, 12(2), 271-281.
Bryant RJ, Pawlowski T, Catto JWF, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T & Hamdy FC (2012) Changes in circulating microRNA levels associated with prostate cancer.. Br J Cancer, 106(4), 768-774. View this article in WRRO
Rosario DJ, Lane JA, Metcalfe C, Donovan JL, Doble A, Goodwin L, Davis M, Catto JWF, Avery K, Neal DE & Hamdy FC (2012) Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.. BMJ, 344, d7894. View this article in WRRO
Drayton RM, Dudziec E, Catto JWF & Bryant HE (2012) Abstract A10: MicroRNA 27a is downreguated in cisplatin resistant bladder cancer cells, and contributes to resistance through the targeting of xCT, a cystine transporter involved with glutathione production. Cancer Research, 72(2 Supplement), A10-A10.
Martínez-Alvarado O, Gray SL, Catto JL & Clark PA (2012) Sting jets in intense winter North-Atlantic windstorms. Environmental Research Letters, 7(2), 024014-024014.
Catto JL, Jakob C & Nicholls N (2012) The influence of changes in synoptic regimes on north Australian wet season rainfall trends. Journal of Geophysical Research: Atmospheres, 117(D10), n/a-n/a.
Catto JL, Jakob C, Berry G & Nicholls N (2012) Relating global precipitation to atmospheric fronts. Geophysical Research Letters, 39(10), n/a-n/a.
Noon AP, Pickvance SMJ & Catto JWF (2012) Occupational exposure to crack detection dye penetrants and the potential for bladder cancer. Occupational and Environmental Medicine, 69(4), 300-301.
Holmberg L, Robinson D, Sandin F, Bray F, Linklater KM, Klint Å, Lambert PC, Adolfsson J, Hamdy FC, Catto J & Møller H (2012) A comparison of prostate cancer survival in England, Norway and Sweden: A population-based study. Cancer Epidemiology, 36(1), e7-e12.
Rosario DJ, Lane JA, Metcalfe C, Donovan JL, Doble A, Goodwin L, Davis M, Catto JWF, Avery K, Neal DE & Hamdy FC (2012) Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study. BMJ, 344(7840).
Noon AP, Pickvance SMJ & Catto JWF (2012) Occupational exposure to crack detection dye penetrants and the potential for bladder cancer.. Occup Environ Med, 69(4), 300-301.
Catto JL, Shaffrey LC & Hodges KI (2011) Northern Hemisphere Extratropical Cyclones in a Warming Climate in the HiGEM High-Resolution Climate Model. Journal of Climate, 24(20), 5336-5352.
Linton KD & Catto JWF (2011) Words of wisdom. Re: Comorbidity and mortality results from a randomised prostate cancer screening trial.. Eur Urol, 60(4), 867.
Catto JWF, Robinson MC, Albertsen PC, Goepel JR, Abbod MF, Linkens DA, Davis M, Rosario DJ, Warren AY, Varma M , Griffiths DF et al (2011) Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study.. Br J Cancer, 105(7), 931-937. View this article in WRRO
Cebrian V, Fierro M, Orenes-Piñero E, Grau L, Moya P, Ecke T, Alvarez M, Gil M, Algaba F, Bellmunt J , Cordon-Cardo C et al (2011) KISS1 Methylation and Expression as Tumor Stratification Biomarkers and Clinical Outcome Prognosticators for Bladder Cancer Patients. The American Journal of Pathology, 179(2), 540-546.
Linton KD & Catto JWF (2011) Gastrointestinal toxicity following radiotherapy for prostate cancer: a ring of fire.. Eur Urol, 60(5), 917-919.
Jerónimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JWF, Clark SJ, Henrique R, Nelson WG & Shariat SF (2011) Epigenetics in prostate cancer: biologic and clinical relevance.. Eur Urol, 60(4), 753-766.
MacLennan SJ, MacLennan SJ, Imamura M, Omar MI, Vale L, Lam T, Royle P, Royle J, Swami S, Pickard R , McClinton S et al (2011) Urological cancer care pathways: development and use in the context of systematic reviews and clinical practice guidelines. World Journal of Urology, 29(3), 291-301. View this article in WRRO
Catto JWF (2011) Thirty-five years of intravesical bacillus Calmette-Guérin for bladder cancer: where now?. Eur Urol, 60(1), 37-38.
Catto JWF (2011) Health care spending, social policy, public health, and life expectancy: what cancer outcomes can tell us beyond treatment efficacy.. Eur Urol, 60(1), 16-18.
Blick C, McCormick R, Ramachandran A, Cranston D, Catto JWF & Harris AL (2011) 495 THE HYPOXIC REGULATION OF FGFR3 IN NON MUSCLE INVASIVE BLADDER CANCER. European Urology Supplements, 10(2), 167-167.
Miah S, Dudziec E, Rosario DJ, Hamdy FC & Catto JW (2011) URINARY MICRORNA IN BLADDER CANCER - A POTENTIAL DIAGNOSTIC TOOL. EUR UROL SUPPL, 10(2), 81-81.
Catto JWF (2011) Improving the outcome for invasive bladder cancer: the debate regarding pelvic lymphadenectomy moves from if to how.. Eur Urol, 59(5), 719-720.
Gardiner RA, Teng L, Buck M, Hancock J, Clarke R, Samaratunga H, Schirra HJ, Zenzmaier C, Berger P, Catto J , Yaxley J et al (2011) Multiple markers in prostate cancer detection from ejaculate. BJU INTERNATIONAL, 107, 28-28.
Catto JWF, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T & Visakorpi T (2011) MicroRNA in prostate, bladder, and kidney cancer: a systematic review.. Eur Urol, 59(5), 671-681.
Courtenay WJ, Miethke J, Rexroth F, Verger J, Catto J, Hobbins D & Lambertini R (2011) Educationand societyinthe middle ages and renaissance. Education and Society in the Middle Ages and Renaissance, 38, 1-952.
Holmberg L, Robinson D, Sandin F, Bray F, Linklater KM, Klint A, Lambert PC, Adolfsson J, Hamdy FC, Catto J & Møller H (2011) A comparison of prostate cancer survival in England, Norway and Sweden: A population-based study. Cancer Epidemiology.
Jerónimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JWF, Clark SJ, Henrique R, Nelson WG & Shariat SF (2011) Epigenetics in prostate cancer: Biologic and clinical relevance. European Urology, 60(4), 753-766.
Linton KD & Catto JWF (2011) Gastrointestinal Toxicity Following Radiotherapy for Prostate Cancer: A Ring of Fire. European Urology.
Catto JWF (2011) Health care spending, social policy, public health, and life expectancy: What cancer outcomes can tell us beyond treatment efficacy. European Urology, 60(1), 16-18.
Catto JWF (2011) Thirty-five years of intravesical bacillus Calmette-Guérin for bladder cancer: Where now?. European Urology, 60(1), 37-38.
Dudziec E, Goepel JR & Catto JWF (2011) Global epigenetic profiling in bladder cancer. Epigenomics, 3(1), 35-45.
Ward JR, Heath PR, Catto JW, Whyte MKB, Milo M & Renshaw SA (2011) Regulation of neutrophil senescence by microRNAs.. PLoS One, 6(1), e15810. View this article in WRRO
Choudhry H & Catto JWF (2011) Epigenetic regulation of microRNA expression in cancer.. Methods Mol Biol, 676, 165-184.
Dudziec E, Miah S, Choudhry HMZ, Owen HC, Blizard S, Glover M, Hamdy FC & Catto JWF (2011) Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer.. Clin Cancer Res, 17(6), 1287-1296.
Barros ATM, Koller WW, Catto JB & Soares CO (2010) Stomoxys calcitrans outbreaks in pastured beef cattle in the state of Mato Grosso do Sul, Brazil. Pesquisa Veterinaria Brasileira, 30(11), 945-952.
Owen HC, Giedl J, Wild PJ, Fine SW, Humphrey PA, Dehner LP, Amin MB, Epstein JI, Blaszyk H, Hughes D , Hartmann A et al (2010) Low frequency of epigenetic events in urothelial tumors in young patients.. J Urol, 184(2), 459-463.
Catto JWF & Chapple CR (2010) Urological diagnosis – history and investigations. Surgery (Oxford), 28(7), 323-330.
Clarke RA, Schirra HJ, Catto JW, Lavin MF & Gardiner RA (2010) Markers for detection of prostate cancer. Cancers, 2(2), 1125-1154. View this article in WRRO
Catto JL, Shaffrey LC & Hodges KI (2010) Can Climate Models Capture the Structure of Extratropical Cyclones?. Journal of Climate, 23(7), 1621-1635.
Macefield RC, Metcalfe C, Lane JA, Donovan JL, Avery KNL, Blazeby JM, Down L, Neal DE, Hamdy FC & Vedhara K (2010) Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. British Journal of Cancer, 102(9), 1335-1340. View this article in WRRO
Sczesny-Moraes EA, Bianchin I, da Silva KF, Catto JB, Honer MR & Paiva F (2010) Anthelmintic resistance of gastrointestinal nematodes in sheep, Mato Grosso do Sul, Brazil. Pesquisa Veterinaria Brasileira, 30(3), 229-236.
Catto JWF, Abbod MF, Wild PJ, Linkens DA, Pilarsky C, Rehman I, Rosario DJ, Denzinger S, Burger M, Stoehr R , Knuechel R et al (2010) The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression.. Eur Urol, 57(3), 398-406. View this article in WRRO
Catto JWF & Hamdy FC (2010) Targeting chemotherapy to advanced bladder cancer patients most likely to benefit.. Future Oncol, 6(2), 193-196.
Miah S & Catto JWF (2010) Haematuria. Surgery, 28(12), 589-593.
Catto JWF & Hamdy FC (2010) Reply from Authors re: David J. DeGraff. Novel Use of a Combined Artificial Intelligence Approach to Identify Patients with Noninvasive Urothelial Cell Carcinoma of the Urinary Bladder Who Are at Greatest Risk for Progression to Muscle-Invasive Disease: A Step Forward. Eur Urol 2010;57:407-8. European Urology, 57(3), 408-409.
Yates DR & Catto JWF (2010) Time to change our approach to high-risk nonmuscle-invasive bladder cancer management in the United Kingdom? Observations from the British association of urological surgeons cancer registry. BJU International, 106(5), 593-594.
Catto JWF (2010) The role of genomic instability in the molecular pathogenesis of transitional cell carcinoma..
Catto JWF, Miah S, Owen HC, Bryant H, Myers K, Dudziec E, Larré S, Milo M, Rehman I, Rosario DJ , Di Martino E et al (2009) Distinct microRNA alterations characterize high- and low-grade bladder cancer.. Cancer Res, 69(21), 8472-8481.
Catto JB, Bianchin I, Santurio JM, Feijó GLD, Kichel AN & Silva JMD (2009) Sistema de pastejo, rotenona e controle de parasitas em bovinos cruzados: efeito no ganho de peso e no parasitismo. Revista Brasileira de Parasitologia Veterinária, 18(04), 37-43.
Abbod MF, Hamdy FC, Linkens DA & Catto JW (2009) Predictive modeling in cancer: where systems biology meets the stock market.. Expert Rev Anticancer Ther, 9(7), 867-870.
Miah S, Owen H, Dudziec E, Rosario D, Hamdy F & Catto J (2009) The differential expression of microRNAs in bladder cancer is associated with altered gene expression. BJU INTERNATIONAL, 103, 19-19.
Catto JWF (2009) Words of wisdom. Re: Sequence variant on 8q24 confers susceptibility to urinary bladder cancer.. Eur Urol, 55(6), 1487-1488.
Catto JWF, Abbod MF, Linkens DA, Larré S, Rosario DJ & Hamdy FC (2009) Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.. Clin Cancer Res, 15(9), 3150-3155.
van Oers JMM, Zwarthoff EC, Rehman I, Azzouzi A-R, Cussenot O, Meuth M, Hamdy FC & Catto JWF (2009) FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.. Eur Urol, 55(3), 650-657.
Santos SA, Abreu UGPD, Souza GDSE & Catto JB (2009) Condição corporal, variação de peso e desempenho reprodutivo de vacas de cria em pastagem nativa no Pantanal. Revista Brasileira de Zootecnia, 38(2), 354-360.
Evans CA, Glen A, Eaton CL, Larre S, Catto JWF, Hamdy FC, Wright PC & Rehman I (2009) Prostate cancer proteomics: The urgent need for clinically validated biomarkers. PROTEOM CLIN APPL, 3(2), 197-212.
Cross SS, Lippitt J, Mitchell A, Hollingsbury F, Balasubramanian SP, Reed MWR, Eaton C, Catto JW, Hamdy F & Winder SJ (2008) Expression of beta-dystroglycan is reduced or absent in many human carcinomas.. Histopathology, 53(5), 561-566.
Cezar AS, Catto JB & Bianchin I (2008) Controle alternativo de nematódeos gastrintestinais dos ruminantes: atualidade e perspectivas. Ciência Rural, 38(7), 2083-2091.
Catto J, Miah S & Hamdy F (2008) UIJ - MicroRNA profiling of bladder cancer. UroToday International Journal, 1(3 SUPPL.).
Rosario DJ, Catto JW, Cutinha PE, Anderson JB, Ferguson C, Kirkbride P & Hamdy FC (2008) Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center: in regard to Kotwal et al. (Int J Radiat Oncol Biol Phys 2008;70:456-463).. Int J Radiat Oncol Biol Phys, 71(5), 1601-1602.
Catto JWF (2008) More nomograms or better evidence of efficacy: what do we need in urologic oncology?. Eur Urol, 54(1), 11-12.
Rouprêt M, Hupertan V, Yates DR, Comperat E, Catto JWF, Meuth M, Lackmichi A, Ricci S, Lacave R, Gattegno B , Richard F et al (2008) A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis.. BJU Int, 101(11), 1448-1453.
Rosario DJ, Lane JA, Metcalfe C, Catto JW, Dedman D, Donovan JL, Neal DE, Hamdy FC & ProtecT Study Group (2008) Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.. Eur Urol, 53(4), 777-784.
Rehman I, Glen A, Gan CS, Hamdy FC, Eaton CL, Cross SS, Catto JWF & Wright PC (2008) ITRAQ-FACILITATED PROTEOMIC ANALYSIS OF HUMAN PROSTATE CANCER CELLS IDENTIFIES PROTEINS ASSOCIATED WITH PROGRESSION. European Urology Supplements, 7(3), 252-252.
Glen A, Gan CS, Hamdy FC, Eaton CL, Cross SS, Catto JWF, Wright PC & Rehman I (2008) iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression.. J Proteome Res, 7(3), 897-907.
Rouprêt M, Hupertan V, Catto JWF, Yates DR, Rehman I, Proctor LM, Phillips J, Meuth M, Cussenot O & Hamdy FC (2008) Promoter hypermethylation in circulating blood cells identifies prostate cancer progression.. Int J Cancer, 122(4), 952-956.
Catto J, Maih S & Hamdy F (2008) MicroRNA profiling of bladder cancer. UroToday International Journal, 01(03).
Bryant RJ & Catto JWF (2008) Haematuria. Surgery, 26(4), 150-153.
Catto JWF (2008) Old and New Urinary Markers: Which One is the PSA for Bladder Cancer?. European Urology, Supplements, 7(5), 422-425.
Catto JWF & Chapple CR (2008) Urological diagnosis - history and investigations. Surgery, 26(4), 154-160.
Catto J (2007) THE BURDEN AND CONSCIENCE OF GOVERNMENT IN THE FIFTEENTH CENTURY. Transactions of the Royal Historical Society, 17, 83-99.
Leiblich A, Cross SS, Catto JWF, Pesce G, Hamdy FC & Rehman I (2007) Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A.. Prostate, 67(16), 1761-1769.
Abbod MF, Catto JWF, Linkens DA & Hamdy FC (2007) Application of artificial intelligence to the management of urological cancer.. J Urol, 178(4 Pt 1), 1150-1156.
Stansfield P, Wigley G, Justham T, Catto J & Pitcher G (2007) PIV analysis of in-cylinder flow structures over a range of realistic engine speeds. Experiments in Fluids, 43(1), 135-146.
Bianchin I, Catto JB, Kichel AN, Torres RAA & Honer MR (2007) The effect of the control of endo- and ectoparasites on weight gains in crossbred cattle (Bos taurus taurus × Bos taurus indicus) in the central region of Brazil. Tropical Animal Health and Production, 39(4), 287-296.
Catto JWF, Yates DR, Rehman I, Azzouzi AR, Patterson J, Sibony M, Cussenot O & Hamdy FC (2007) Behavior of urothelial carcinoma with respect to anatomical location.. J Urol, 177(5), 1715-1720.
Azzouzi A-R, Catto JWF, Rehman I, Larre S, Roupret M, Feeley KM, Cussenot O, Meuth M & Hamdy FC (2007) Clinically localised prostate cancer is microsatellite stable.. BJU Int, 99(5), 1031-1035.
Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, Linkens DA, Hamdy FC & Catto JWF (2007) Promoter hypermethylation identifies progression risk in bladder cancer.. Clin Cancer Res, 13(7), 2046-2053.
Rouprêt M, Hupertan V, Yates DR, Catto JWF, Rehman I, Meuth M, Ricci S, Lacave R, Cancel-Tassin G, de la Taille A , Rozet F et al (2007) Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage.. Clin Cancer Res, 13(6), 1720-1725.
Catto J, Abbod M, Linkens D, Wild P, Herr A, Wissman C, Pilarsky C, Hartmann A & Hamdy F (2007) 381 IMPROVING GENE ARRAY ANALYSIS: THE APPLICATION OF ARTIFICIAL INTELLIGENCE IDENTIFIES NOVEL BIOMARKERS OF SUPERFICIAL BLADDER CANCER PROGRESSION. European Urology Supplements, 6(2), 118-118.
Catto J, Yates DR, Chapman N, Rehman I & Hamdy FA (2007) 487 METHYL-CPG BINDING PROTEIN OCCUPANCY IN BLADDER CANCER: AN ANALYSIS OF GENE PROMOTERS WITH VARIABLE CPG METHYLATION AND HISTONE MODIFICATIONS. European Urology Supplements, 6(2), 144-144.
Rouprêt M, Hupertan V, Yates DR, Catto JWF, Rehman I, Meuth M, Ricci S, Lacave R, De La Taille A, Rozet F , Cathelineau X et al (2007) 500 MOLECULAR DIAGNOSIS OF LOCALIZED PROSTATE CANCER BY QUANTITATIVE METHYLATION-SPECIFIC PCR GENE PATTERNS IN URINE CELLS OBTAINED BY PROSTATE MASSAGE. European Urology Supplements, 6(2), 147-147.
Roupret M, Hupertan V, Yates DR, Catto JWF, Rehman I, Meuth M, Ricci S, Lacave R, Richard F, Gattegno B , Hamdy FC et al (2007) 379 COMPARED PERFORMANCE OF MICROSATELLITE AND METHYLATION URINALYSIS IN PREDICTING RECURRENCE IN TRANSITIONAL CELL CARCINOMA AND DEFINITION OF A DIAGNOSTIC PANEL OF MARKERS BY BAYESIAN NETWORK ANALYSIS. European Urology Supplements, 6(2), 117-117.
Catto J, Yates DR, Rehman I, Patterson J, Sibony M, Cussenot O & Hamdy FC (2007) 361 A COMPARATIVE ANALYSIS OF THE BEHAVIOUR OF UROTHELIAL CARCINOMA WITH RESPECT TO ANATOMICAL LOCATION. European Urology Supplements, 6(2), 113-113.
Rehman I, Goodarzi A, Cross SS, Leiblich A, Catto JWF, Phillips JT & Hamdy FC (2007) DNA methylation and immunohistochemical analysis of the S100A4 calcium binding protein in human prostate cancer.. Prostate, 67(4), 341-347.
Marín-Aguilera M, Mengual L, Ribal MJ, Musquera M, Ars E, Villavicencio H, Algaba F & Alcaraz A (2007) Utility of Fluorescence In Situ Hybridization as a Non-invasive Technique in the Diagnosis of Upper Urinary Tract Urothelial Carcinoma. European Urology, 51(2), 409-415.
Abbod MF, Catto JWF, Chen M, Linkens DA & Hamdy FC (2007) Artificial Intelligence techniques for the prediction of bladder cancer progression. ESANN 2005 Proceedings - 13th European Symposium on Artificial Neural Networks, 109-114.
Wild PJ, Catto JWF, Abbod MF, Linkens DA, Herr A, Pilarsky C, Wissmann C, Stoehr R, Denzinger S, Knuechel R , Hamdy FC et al (2007) Artificial intelligence and bladder cancer arrays.. Verh Dtsch Ges Pathol, 91, 308-319.
Wild P, Catto JWF, Abbod MF, Linkens DA, Herr A, Pilarsky C, Wissmann C, Hamdy FC & Hartmann A (2007) Improving gene array analysis: The application of artificial intelligence identifies novel biomarkers of non invasive papillary bladder cancer progression. PATHOLOGY RESEARCH AND PRACTICE, 203(5), 278-279.
Burger M, Denzinger S, Hammerschmied C, Tannapfel A, Maderstorfer A, Wieland WF, Hartmann A & Stoehr R (2006) Mitogen-Activated Protein Kinase Signaling is Activated in Prostate Tumors but not Mediated by B-RAF Mutations. European Urology, 50(5), 1102-1110.
Catto J (2006) Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations - Editorial comment. EUROPEAN UROLOGY, 50(5), 1109-1110.
Catto JWF (2006) The changing face of prostate cancer: can gains in epigenetic knowledge translate into improvements in clinical care?. J Mol Med (Berl), 84(11), 883-885.
Catto J (2006) Re: Novel Blood Biomarkers of Human Urinary Bladder Cancer. European Urology, 50(4), 862-862.
Dhawan D, Hamdy FC, Rehman I, Patterson J, Cross SS, Feeley KM, Stephenson Y, Meuth M & Catto JWF (2006) Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.. J Pathol, 209(3), 336-343.
Catto JWF, Hartmann A, Stoehr R, Bolderson E, Rehman I, Rosario DJ, Hamdy FC & Meuth M (2006) Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance.. J Urol, 175(6), 2323-2330.
Leiblich A, Cross SS, Catto JWF, Phillips JT, Leung HY, Hamdy FC & Rehman I (2006) Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer.. Oncogene, 25(20), 2953-2960.
Yates D, Rehman I, Cross S, Meuth M, Hamdy F & Catto JW (2006) A GENE-PROMOTER HYPERMETHYLATION PANEL TO DETECT TRANSITIONAL CELL CARCINOMA OF THE BLADDER. European Urology Supplements, 5(2), 37-37.
Rouprêt M, Fromont G, Cancel-Tassin G, Azzouzi AR, Catto JW, Hamdy FC, Vallancien G, Richard F & Cussenot O (2006) MICROSATELLITE INSTABILITY AS PREDICTOR OF SURVIVAL IN PATIENTS WITH INVASIVE UPPER URINARY TRACT TRANSITIONAL CELL CARCINOMA. European Urology Supplements, 5(2), 114-114.
Yates DR, Rehman I, Meuth M, Cross SS, Hamdy FC & Catto JWF (2006) Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls.. Oncogene, 25(13), 1984-1988.
DHAWAN D, MEUTH M, CUSSENOT O, AZZOUZI AR & HAMDY FC (2006) 23 DNA promoter methylation in urothelial cancer: a feature of the invasive phenotype and a novel therapeutic target. BJU International, 97, 7-7.
YATES DR, REHMAN I, MEUTH M, CROSS SS & HAMDY FC (2006) 22 A gene promoter hypermethylation panel to detect transitional cell carcinoma of the bladder. BJU International, 97, 6-7.
CROSS S, PHILLIPS J, LEIBLICH A, LEUNG H, HAMDY FC & REHMAN I (2006) 21 Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer. BJU International, 97, 6-6.
Catto JWF, Abbod MF, Linkens DA & Hamdy FC (2006) Neuro-fuzzy modeling: an accurate and interpretable method for predicting bladder cancer progression.. J Urol, 175(2), 474-479.
Abbod MF, Catto JWF, Linkens DA, Wild PJ, Herr A, Wissmann C, Pilarsky C, Hartmann A & Hamdy FC (2006) Artificial intelligence technique for gene expression profiling of urinary bladder cancer. IEEE Intelligent Systems, 646-651.
Yates D & Catto JW (2006) Investigation of haematuria. Foundation Years, 2(2), 80-82.
Burger M, Catto J, van Oers J, Zwarthoff E, Hamdy FC, Meuth M, Azzouri AR, Cussenot O, Wild PJ, Stoehr R & Hartmann A (2006) Mutation of the FGFR3 oncogene is an independent and favorable prognostic factor for tumor-specific survival in patients with urothelial carcinoma of the upper urinary tract. Verhandlungen der Deutschen Gesellschaft für Pathologie, 90, 244-252.
Abbod MF, Linkens DA, Catto JWF & Hamdy FC (2006) Comparative study of intelligent models for the prediction of bladder cancer progression.. Oncol Rep, 15 Spec no., 1019-1022.
Rehman I, Cross SS, Catto JWF, Leiblich A, Mukherjee A, Azzouzi A-R, Leung HY & Hamdy FC (2005) Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer.. Prostate, 65(4), 322-330.
Phillips J, Catto JWF, Lavin V, Doyle D, Smith DJ, Hastie KJ & Oakley NE (2005) The laparoscopic nephrectomy learning curve: a single centre's development of a de novo practice.. Postgrad Med J, 81(959), 599-603.
Catto JB, Bianchin I & Torres RAA (2005) Effects of deworming of cow-calf beef herds in brazilian savannas. Pesquisa Veterinaria Brasileira, 25(3), 188-194.
Leal AT, Santurio JM, Leal ABM, Catto JB, Flores EF, Lubeck I & Alves SH (2005) Characterization of the specificity of the humoral response to Pythium insidiosum antigens. Journal de Mycologie Médicale, 15(2), 63-68.
Yates D, Dhawan D, Patterson J, Meuth M, Hamdy FC & Catto JWF (2005) Aberrant promoter methylation in pre-malignant and invasive tumours of the urinary bladder. BJU INTERNATIONAL, 95, 65-65.
Yates DR, Catto JWF, Rehman I, Meuth M, Cross S & Hamdy FC (2005) Comparing gene promoter methylation frequencies in urine from patients with bladder cancer with urine from non-cancerous young and elderly control patients. BJU INTERNATIONAL, 95, 63-64.
Rouprêt M, Fromont G, Azzouzi A-R, Catto JW, Vallancien G, Hamdy FC & Cussenot O (2005) Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma.. Urology, 65(6), 1233-1237.
Catto JWF, Azzouzi A-R, Rehman I, Feeley KM, Cross SS, Amira N, Fromont G, Sibony M, Cussenot O, Meuth M & Hamdy FC (2005) Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.. J Clin Oncol, 23(13), 2903-2910.
Catto JWF, Natarajan V & Tophill PR (2005) Simultaneous augmentation cystoplasty is associated with earlier rather than increased artificial urinary sphincter infection.. J Urol, 173(4), 1237-1241.
Leiblich A, Cross S, Catto J, Azzouzi A, Hamdy F & Rehman I (2005) 621Promoter hyper-methylation of lactate dehydrogenase-B is associated with prostate cancer development. European Urology Supplements, 4(3), 158-158.
Catto J, Dhawan D, Azzouzi AR, Mukherjee A, Rehman I, Patterson J, Cross S, Meuth M & Hamdy F (2005) 332Epigenetic alterations in premalignant lesions of the urinary bladder. European Urology Supplements, 4(3), 85-85.
Rouprêt M, Catto J, Coulet F, Azzouzi AR, Fromont G, Sibony M, Vallancien G, Gattegno B, Hamdy F & Cussenot O (2005) 474Microsatellite instability as indicator of MSH2 gene mutation in patients with upper urinary tract transitional cell carcinoma. European Urology Supplements, 4(3), 121-121.
Rehman I, Cross S, Catto J, Mukherjee A, Azzouzi AR & Hamdy F (2005) 623Frequent promoter hyper-methylation of the S100A6 calcium binding protein in human prostate cancer. European Urology Supplements, 4(3), 158-158.
Yates DR & Catto JWF (2005) Haematuria. Surgery (Oxford), 23(3), 114-116.
Catto JWF, Hartmann A, Azzouzi AR, Rehman I, Feeley K, Meuth M & Hamdy F (2005) 64 Promoter methylation and microsatellite mutation reveals the clonal relationship of multiple transitional cell carcinoma with the mutator phenotype. European Urology Supplements, 4(3), 18-18.
Catto JWF & Chapple CR (2005) Urological diagnosis: history, examination and investigations. Surgery (Oxford), 23(3), 108-113.
Catto JW & Chapple CR (2005) Assessing the patient with a urological problem. Foundation Years, 1(3), 1-7.
Stöhr R, Catto JW, Azzouzi A, Rehmann I, Feeley K, Meuth M, Hamdy F, Burger M & Hartmann A (2005) Promoter methylation and microsatellite mutation reveals the clonal relationship of multiple urothelial carcinomas with mutator phenotype. Verhandlungen der Deutschen Gesellschaft für Pathologie, 89, 225-233.
Catto JWF & Rosario DJ (2005) The road to cystectomy: Who, when and why?. EAU Update Series, 3(3 SPEC. ISS.), 118-128.
Catto JWF & Hamdy FC (2005) The role of genetic instability in the pathogenesis and progression of urothelial carcinoma. EAU Update Series, 3(4), 180-188.
Rehman I, Azzouzi AR, Catto JWF & Hamdy FC (2005) The use of proteomics in urological research. EAU Update Series, 3(4), 171-179.
Stöhr R, Catto JWF, Azzouzi A, Rehmann I, Feeley K, Meuth M, Hamdy F, Burger M & Hartmann A (2005) [Promoter methylation and microsatellite mutation reveals the clonal relationship of multiple urothelial carcinomas with mutator phenotype].. Verh Dtsch Ges Pathol, 89, 225-233.
Hamdy FC & Catto JWF (2004) Less is more: artificial intelligence and gene-expression arrays.. Lancet, 364(9450), 2003-2004.
Rehman I, Azzouzi AR, Catto JWF, Allen S, Cross SS, Feeley K, Meuth M & Hamdy FC (2004) Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study.. Urology, 64(6), 1238-1243.
Rehman I, Azzouzi A-R, Cross SS, Deloulme JC, Catto JWF, Wylde N, Larre S, Champigneuille J & Hamdy FC (2004) Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions.. Hum Pathol, 35(11), 1385-1391.
Rehman I, Cross SS, Azzouzi A-R, Catto JWF, Deloulme JC, Larre S, Champigneuille J, Fromont G, Cussenot O & Hamdy FC (2004) S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors.. Br J Cancer, 91(4), 739-744. View this article in WRRO
Roupret M (2004) Microsatellite instability as indicator of MSH2 gene mutation in patients with upper urinary tract transitional cell carcinoma. Journal of Medical Genetics, 41(7), e91-e91.
Rehman I, Azzouzi A-R, Catto J, Allen S, Cross S, Feeley K, Eaton C, Meuth M & Hamdy FC (2004) 1083: Proteomic Analysis of Voided Urine following Prostatic Massage Reveals Tumour Specific Alterations. Journal of Urology, 171(4S), 286-286.
Azzouzi AR, Catto J, Rehman I, Mc Pherson G, Cancel Tassin G, Cox A, Mangin P, Meuth M & Hamdy F (2004) 854 Association of cytochrome P450 1B1 VAL432LEU polymorphism and prostate cancer risk. European Urology Supplements, 3(2), 216-216.
Rehman I, Azzouzi AR, Catto JWF, Allen S, Cross SS, Feeley K, Eaton C, Meuth M & Hamdy FC (2004) 76 Proteomic analysis of voided urine following prostatic massage reveals tumour specific alterations. European Urology Supplements, 3(2), 21-21.
Ahmad M, Catto JWF, Azzouzi AR, Cross SS, Feeley K, Eaton C, Meuth M, Hamdy FC & Rehman I (2004) 205 Proteomics and immunohistochemistry identify loss of nucleophosmin (B23) expression in bladder transitional cell carcinomas. European Urology Supplements, 3(2), 54-54.
Rehman I, Azzouzi AR, Catto JWF, Deloulme JC, Cross SS, Feeley K, Eaton C, Meuth M & Hamdy FC (2004) 452 Calgizzarin (S100A11) immunostaining pattern is altered in prostate cancer suggesting a role in tumourigenesis. European Urology Supplements, 3(2), 115-115.
Abbod MF, Catto JWF, Chen M, Linkens DA & Hamdy FC (2004) Artificial intelligence for the prediction bladder cancer. Biomedical Engineering - Applications, Basis and Communications, 16(2), 49-58.
Catto JWF, Meuth M & Hamdy FC (2004) Genetic instability and transitional cell carcinoma of the bladder.. BJU Int, 93(1), 19-24.
Catto JWF, Azzouzi A-R, Amira N, Rehman I, Feeley KM, Cross SS, Fromont G, Sibony M, Hamdy FC, Cussenot O & Meuth M (2003) Distinct patterns of microsatellite instability are seen in tumours of the urinary tract.. Oncogene, 22(54), 8699-8706.
Catto JWF, Linkens DA, Abbod MF, Chen M, Burton JL, Feeley KM & Hamdy FC (2003) Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks.. Clin Cancer Res, 9(11), 4172-4177.
Catto JWF, Xinarianos G, Burton JL, Meuth M & Hamdy FC (2003) Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability.. Int J Cancer, 105(4), 484-490.
Azzouzi AR, Catto JW, Rehman I, Feeley K, Meuth M & Hamdy FC (2003) Instability at selected microsatellite tetra-nucleotide repeats in prostate cancer. European Urology Supplements, 2(1), 60-60.
Catto JWE, Linkens DA, Abbod MF, Chen M, Meuth M & Handy FC (2003) The application of artificial intelligence in predicting outcome of bladder cancer: A comparison of neuro-fuzzy modelling and artificial neural networks. European Urology Supplements, 2(1), 66-66.
Calvert NW, Morgan AB, Catto JWF, Hamdy FC, Akehurst RL, Mouncey P & Paisley S (2003) Effectiveness and cost-effectiveness of prognostic markers in prostate cancer.. Br J Cancer, 88(1), 31-35. View this article in WRRO
Ahmad M, Catto JWF, Azzouzi AR, Cross SS, Feeley K, Eaton CL, Meuth M, Hamdy FC & Rehman I (2003) Proteomics and immunohistochemistry identify loss of nucleophosmin (B23) expression in bladder transitional cell carcinomas. European Urology, Supplements, 2(6), 69.
Rehman I, Azzouzi AR, Catto JWF, Allen S, Cross SS, Feeley K, Eaton CL, Meuth M & Harndy FC (2003) Proteomic analysis of voided urine following prostatic massage reveals tumour specific alterations. European Urology, Supplements, 2(6), 70.
Rehman I, Azzouzi AR, Catto JWF, Ahmad M, Deloulme UC, Cross SS, Feeley K, Eaton CL, Meuth M & Hamdy FC (2003) Calgizzarin (S100A11) immunostaining pattern is altered in prostate cancer suggesting a role in tumourigenesis. European Urology, Supplements, 2(6), 68.
Catto JWF & Hamdy FC (2002) Haematuria. Surgery (Oxford), 20(11), 255-257.
Catto JWF & Chapple CR (2002) Urological Diagnosis: History and Investigations. Surgery (Oxford), 20(11), 249-254.
Catto JWF & Alexander DJ (2002) Pancreatic debridement in a district general hospital--viable or vulnerable?. Ann R Coll Surg Engl, 84(5), 309-313.
Catto J, Xinarianos G, Burton J, Meuth M & Hamdy F (2002) Differential expression of mismatch repair proteins, MLH1 and MSH2, in Transitional Cell Carcinoma (TCC) of the bladder. European Urology Supplements, 1(1), 22-22.
Leal ABM, Leal AT, Santurio JM, Kommers GD & Catto JB (2001) Equine pythiosis in the Brazilian Pantanal region: Clinical and pathological findings of typical and atypical cases. Pesquisa Veterinaria Brasileira, 21(4), 151-156.
Ward AM, Catto JW & Hamdy FC (2001) Prostate specific antigen: biology, biochemistry and available commercial assays.. Ann Clin Biochem, 38(Pt 6), 633-651.
Catto JB & Afonso E (2001) Natality rate of cows and development of calves submitted to early weaning in the Pantanal region, Brazil. Pesquisa Agropecuaria Brasileira, 36(9), 1205-1211.
Sereno JRB, Catto JB, Da Silva MPDA & De Souza Sereno FTP (2000) Alternative management for weaned Nelore calves in the Pantanal's native pastures. Pesquisa Agropecuaria Brasileira, 35(10), 2099-2105.
Cohen LD, Alexander DJ, Catto J & Mannion R (2000) Spontaneous Transpyloric Migration of a Ballooned Nasojejunal Tube: A Randomized Controlled Trial. Journal of Parenteral and Enteral Nutrition, 24(4), 240-243.
Catto JW, Madan M & Alexander DJ (1999) Hepatobiliary cystadenoma presenting with intermittent inferior vena caval obstruction.. J Hepatobiliary Pancreat Surg, 6(3), 324-326.
Santurio JM, Monteiro AB, Leal AT, Kommers GD, de Sousa RS & Catto JB (1998) . Mycopathologia, 141(3), 123-125.
Catto JW, Hinson F & Alexander DJ (1998) An abdominal mass following a road traffic accident.. Postgrad Med J, 74(874), 501-502.
Hinson FL, Catto JWF & Hall R (1998) Recurrence of adult groin hernias five years after repair in a district general hospital. BRITISH JOURNAL OF SURGERY, 85, 17-17.
Catto JW, Hinson FL & Leveson SH (1998) Topical glyceryl trinitrate cream for anal fissure.. Br J Surg, 85(6), 874-875.
Harris JA, Jury RP, Catto J, Glover JL, Broadie TA, Dieziel DJ & Hanni CL (1995) Closed drainage versus open packing of infected pancreatic necrosis. American Surgeon, 61(7), 612-618.
Costa CA & Catto JB (1994) Helminth parasites of capybaras (Hydrochaeris hydrochaeris) on sub-region of Nhecolândia, Pantanal, Mato Grosso do Sul. Revista brasileira de biologia, 54(1), 39-48.
Catto J (1993) Stoma care. Prescribers' Journal, 33(3), 111-121.
DeRidder PH, Levine AJ, Katta JJ & Catto JA (1989) Angiolipoma of the stomach as a cause of chronic upper gastrointestinal bleeding. Surgical Endoscopy, 3(2), 106-108.
Spiller RC, Catto JVF & Kane SP (1981) Spontaneous Dissecting Intramural Haematoma of the Oesophagus: A Rare Cause of Haematemesis and Dysphagia. Endoscopy, 13(03), 128-130.
Howard RS (1980) Cecal Volvulus. Archives of Surgery, 115(3), 273-273.
Szlabick RE (1980) Hepatobiliary Scanning in the Diagnosis of Acute Cholecystitis. Archives of Surgery, 115(4), 540-540.
Catto J (1976) IDEAS AND EXPERIENCE IN THE POLITICAL THOUGHT OF AQUINAS. Past and Present, 71(1), 3-21.
Lockwood CM, Forster PM, Catto JVF & Stewart JS (1974) A case of duodenal tuberculosis. The American Journal of Digestive Diseases, 19(6), 575-579.
CATTO JI (1967) An alleged Great Council of 1374. The English Historical Review, LXXXII(CCCXXV), 764-771.
Catto JVF (1964) Multiple Liver Abscesses in Hydatid Disease. The British Journal of Radiology, 37(443), 859-860.
Catto JVF (1959) Toxic Epidermal Necrolysis Occurring in a Child. BMJ, 2(5151), 544-545.
Catto J (1905) SCHISTOSOMA CATTOI, A NEW BLOOD FLUKE OF MAN. BMJ, 1(2297), 11-26.
Alexander CE, Nathan A, Light A, Gao C, Chan V, Khadhouri S, Gallagher K, Byrnes KG, Walters M, Hughes T , Perry R et al () Understanding the long‐term impact of the COVID‐19 pandemic on non‐muscle‐invasive bladder cancer outcomes: 12‐Month follow‐up data from the international, prospective COVIDSurg Cancer study. BJUI Compass.
Conroy S, Jubber I, Noon AP, Rosario DJ, Griffin J, Morgan S, Hubbard R, Kennish S, Mitchell S, Venugopal S , Linton K et al () Real‐word outcomes for high‐risk non‐muscle‐invasive bladder cancer: screened patients for the BRAVO trial. BJU International.
Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L, Wiechno P, Atduev V , Kann AG et al () Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. New England Journal of Medicine.
Kuppanda P, Hermans L, Uren A, Cotterill N, Rowe E, Narahari K, Dickinson A, Rigby J & Aning J () National audit of patient reported experience of radical cystectomy for bladder cancer pathways. BJUI Compass.
James N, Pirrie S, Liu W, Catto J, Jefferson K, Patel P, Hughes A, Pope A, Nanton V, Mintz HP , Knight A et al () Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT. Health Technology Assessment, 1-65.
Dhar A, Siriwardana A, Schofield E & Catto JWF () Blood Transfusion, Radical Cystectomy, and Cancer Recurrence: A New Look at an Old Story. Comment on Ladner et al. Perioperative Blood Transfusion Is Associated with Worse Survival in Patients Undergoing Radical Cystectomy after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. Soc. Int. Urol. J. 2024, 5, 202–213. Société Internationale d’Urologie Journal, 5(3), 244-246.
Birtle AJ, Jones R, Chester J, Lewis R, Biscombe K, Johnson M, Blacker A, Bryan R, Catto JWF, Choudhury A , Das P et al () Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial. Journal of Clinical Oncology.
Panebianco V, Briganti A, Boellaard TN, Catto J, Comperat E, Efstathiou J, van der Heijden AG, Giannarini G, Girometti R, Mertens L , Takeuchi M et al () Clinical application of bladder MRI and the Vesical Imaging-Reporting And Data System. Nature Reviews Urology.
Rogers Z, Glaser A, Catto JWF, Bottomley S, Jubber I, Kotwal S, Brittain P, Gill J, Rogers MA, Dooldeniya MD , Koenig P et al () Quality of life after a diagnosis of Bladder Cancer: Longitudinal survey over the first year. BJU International.
Kaufmann E, Black PC, Catto JWF, Djaladat H, Ghodoussipour S, Hamilton-Reeves JM, Jensen BT, Kassouf W, Lauridsen SV, Lerner SP , Llorente C et al () Functional Follow-Up After Cystectomy and Urinary Diversion: A Narrative Review. JU Open Plus, 1(11).
Kaufmann E, Black PC, Catto JWF, Djaladat H, Ghodoussipour S, Hamilton-Reeves JM, Jensen BT, Kassouf W, Lauridsen SV, Lerner SP , Llorente C et al () Oncological Surveillance After Radical Cystectomy: a Narrative Review of the Enhanced Recovery After Surgery Cystectomy Committee. JU Open Plus, 1(10).
Conroy S, Catto JWF, Bex A, Brown J, Cartledge J, Fielding A, Jones RJ, Khoo V, Nicol D, Stewart GD , Sullivan M et al () Diagnosis, treatment, and survival from kidney cancer: real‐world NHS England data between 2013‐2019. BJU International.
Vickers A, O’Brien F, Montorsi F, Galvin D, Bratt O, Carlsson S, Catto JWF, Krilaviciute A, Philbin M & Albers P () Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit. BMJ, e071082-e071082.
Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, Martin RM, Young GJ, Walsh EI, Bryant RJ , Bollina P et al () Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. New England Journal of Medicine.
Catto JWF, Mandrik O, Quayle LA, Hussain SA, McGrath J, Cresswell J, Birtle AJ, Jones RJ, Mariappan P, Makaroff LE , Knight A et al () Diagnosis, treatment and survival from bladder, upper urinary tract and urethral cancers: Real world findings from NHS England between 2013 and 2019. BJU International.
Baxter L, Gordon NS, Ott S, Wang J, Patel P, Goel A, Piechocki K, Silcock L, Sale C, Zeegers MP , Cheng KK et al () Properties of non-coding mutation hotspots as urinary biomarkers for bladder cancer detection. Scientific Reports, 13(1).
Griffin J, Chen Y, Catto JWF & El-Khamisy S () Gene of the month: NKX3.1. Journal of Clinical Pathology.
Dajti I, Valenzuela JI, Boccalatte LA, Gemelli NA, Smith DE, Dudi-Venkata NN, Kroon HM, Sammour T, Roberts M, Mitchell D , Lah K et al () Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: the COVIDSurg mortality score. British Journal of Surgery.
Uren A, Cotterill N, Abrams P, Catto JWF, Patel B, McGrath J, Ahmed I & Rowe E () The development of the C‐PAT: a concise tool to assess the quality of care in the cystectomy pathway. BJU International.
Bin Riaz I, Khan AM, Catto JWF & Hussain SA () Bladder cancer: shedding light on the most promising investigational drugs in clinical trials. Expert Opinion on Investigational Drugs.
Khadhouri S, Gallagher KM, MacKenzie KR, Shah TT, Gao C, Moore S, Zimmermann EF, Edison E, Jefferies M, Nambiar A , Mannas MP et al () The IDENTIFY Study: The Investigation and Detection of Urological Neoplasia in Patients Referred with Suspected Urinary Tract Cancer; A multicentre observational study. BJU International.
Cappuccini F, Bryant R, Pollock E, Carter L, Verrill C, Hollidge J, Poulton I, Baker M, Mitton C, Baines A , Meier A et al () Safety and exceptional immunogenicity of novel 5T4 viral vectored vaccination regimes in early stage prostate cancer: a phase I clinical trial.
Pang KH, Esperto F, Sproson C, Yeung M, Morgan SL, Downey AP, Hillary CJ, Catto JWF, Rosario DJ & Noon AP () Urethral recurrence after radical cystoprostatectomy: Experience from a high-volume tertiary referral centre. Journal of Clinical Urology, 205141582092051-205141582092051.
Brooks NA, Kokorovic A, McGrath JS, Kassouf W, Collins JW, Black PC, Douglas J, Djaladat H, Daneshmand S, Catto JWF , Kamat AM et al () Critical analysis of quality of life and cost-effectiveness of enhanced recovery after surgery (ERAS) for patient’s undergoing urologic oncology surgery: a systematic review. World Journal of Urology.
Hamdy FC, Elliott D, le Conte S, Davies LC, Burns RM, Thomson C, Gray R, Wolstenholme J, Donovan JL, Fitzpatrick R , Verrill C et al () Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT. Health Technology Assessment, 22(52), 1-96.
Bourke L, Smith D, Steed L, Hooper R, Catto J, Albertsen PC, Tombal B, Payne HA & Rosario DJ () Exercise interventions for men with prostate cancer. Cochrane Database of Systematic Reviews.
Bourke L, Smith D, Steed L, Hooper R, Catto J, Albertsen PC, Tombal B, Payne HA & Rosario DJ () Exercise interventions for men with prostate cancer.
Killick E, Tymrakiewicz M, Cieza-Borrella C, Smith P, Thompson DJ, Pooley KA, Easton DF, Bancroft E, Page E, Leongamornlert D , Kote-Jarai Z et al () Telomere Length Shows No Association with BRCA1 and BRCA2 Mutation Status. PLoS ONE, 9(1), e86659-e86659. View this article in WRRO
Catto J, Jakob C & Nicholls N () A global evaluation of fronts and precipitation in the ACCESS model. Australian Meteorological and Oceanographic Journal, 63(1), 191-203.

Chapters

Conroy S & Catto JWF (2023) Muscle-invasive bladder cancer In Pang KH, Catto JWF, Myat A & Haldar S (Ed.), Challenging Cases in Urological Surgery (pp. C12-C12.P147). Oxford University PressOxford
Panebianco V, Messina E, Vargas HA & Catto J (2022) Imaging in Bladder Cancer Surgery, Robotic Urologic Surgery (pp. 627-637). Springer International Publishing
Pang KH & Catto JWF (2021) Prostate Cancer, Basic Urological Sciences (pp. 208-217). CRC Press
Jubber I, Pang KH & Catto JWF (2021) Urothelial and Urethral Cancer, Basic Urological Sciences (pp. 189-207). CRC Press
Pang KH & Catto JWF (2020) Haematuria: Evaluation and Management, Urologic Principles and Practice (pp. 281-286). Springer International Publishing
Pang KH & Catto JWF (2017) How Do I Publish a Scientific Urological Paper?, Practical Tips in Urology (pp. 323-329). Springer London
Eardley I, Noon A & Catto J (2016) Genitourinary malignancies, Oxford Textbook of Fundamentals of Surgery (pp. 373-377). Oxford University Press
Dickman KG, Fritsche H-M, Grollman AP, Thalmann GN & Catto J (2015) Epidemiology and Risk Factors for Upper Urinary Urothelial Cancers, Upper Tract Urothelial Carcinoma (pp. 1-30). Springer New York
Bryant RJ & Catto JWF (2011) Hematuria: Evaluation and Management, Practical Urology: Essential Principles and Practice (pp. 351-359). Springer London
Catto J (2011) 1349–1412: culture and history, The Cambridge Companion to Medieval English Mysticism (pp. 113-132). Cambridge University Press
(2008) The Cambridge History of the Book in Britain Cambridge University Press
Dudziec E & Catto JWF () The epigenetic profile of bladder cancer, Epigenomics (pp. 323-337). Cambridge University Press

Conference proceedings papers

Khetrapal P, Liu Y, Ambler G, Williams NR, Sridhar A, Khan MS, Ahmad I, Charlesworth P, Kotwal S, Rowe E , Hanchanale V et al (2024) REMOTE DIGITAL SURVEILLANCE AND MACHINE LEARNING MODELLING TO PREDICT SURVIVAL FOLLOWING RADICAL CYSTECTOMY FOR BLADDER CANCER-A SECONDARY OUTCOME ANALYSIS OF THE IROC TRIAL. JOURNAL OF UROLOGY, Vol. 211(5) (pp E793-E794)
Crabb SJ, Hussain SA, Oughton JB, Swain J, Cairns DA, Collinson M, Ainsworth G, McCready D, Griffin J, Heath P , Quayle L et al (2024) Use of gene expression patterns to identify unique molecular subtypes in muscle invasive bladder cancer: GUSTO. JOURNAL OF CLINICAL ONCOLOGY, Vol. 42(16)
Khetrapal P, Catto J, Ambler G, Williams N, Al-Hammouri T, Khan MS, Thurairaja R, Nair R, Nathan S, Sridhar A , Ahmad I et al (2023) MEASURING OBJECTIVE RECOVERY OF ACTIVITY LEVELS USING WEARABLE DEVICES FOLLOWING OPEN VS INTRACORPOREAL ROBOTIC CYSTECTOMY: SECONDARY OUTCOMES ANALYSIS OF THE IROC RANDOMIZED TRIAL. JOURNAL OF UROLOGY, Vol. 209 (pp E985-E985)
Griffin J, Down J, Quayle L, Heath P & Catto J (2023) Pathology Against the Clock: Verification of Gene Expression Subtyping for the GUSTO Clinical Trial. JOURNAL OF PATHOLOGY, Vol. 261(SUPPL1) (pp S49-S49)
Cooper O, Rentz A, Piglowska N, Smith C, Jakobsen J, Catto J, Niegisch G, Ghatnekar O & Swinburn P (2022) ELICITATION OF HEALTH STATE UTILITIES ASSOCIATED PROGRESSION FROM BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) HEALTH STATES. VALUE IN HEALTH, Vol. 25(7) (pp S288-S288)
Khetrapal P, Catto J, Ambler G, Ricciardi F, Khan S, Feber A, Dixon S, Williams N, Ahmed I, Charlesworth P , Cumberbatch M et al (2022) RESULTS OF THE INTRACORPOREAL ROBOTIC VS OPEN CYSTECTOMY (IROC) MULTI-CENTRE RANDOMISED TRIAL. JOURNAL OF UROLOGY, Vol. 207(5) (pp E695-E695)
Niazi T, McBride SM, Williams S, Davis ID, Stockler MR, Martin AJ, Bracken K, Roncolato F, Horvath L, Sengupta S , Martin J et al (2022) DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. JOURNAL OF CLINICAL ONCOLOGY, Vol. 40(16)
Tan WS, Leow J, Marchese M, Sridhar A, Hellawell G, Mossanen M, Teoh J, Fowler S, Colquhoun A, Cresswell J , Catto J et al (2021) FACTORS ASSOCIATED WITH HIGH-QUALITY SURGERY FOLLOWING RADICAL CYSTECTOMY: ANALYSIS OF THE BRITISH ASSOCIATION OF UROLOGICAL SURGEONS (BAUS) CYSTECTOMY AUDIT. JOURNAL OF UROLOGY, Vol. 206 (pp E1057-E1058)
Khetrapal* P, Catto J, Norman W, Ambler G, Sarpong R, Khan MS, Thurairaja R, Tan M, Feber A, Dixon S , Goodwin L et al (2020) MP61-06 THE ROLE OF WEARABLE DEVICES AND CPET IN PREDICTING MAJOR COMPLICATIONS AFTER RADICAL CYSTECTOMY. The Journal of Urology, Vol. 203 (pp e937-e937)
Crabb SJ, Huddart RA, Brown E, Dunkley D, Downs N, McDowell C, Catto JWF, Griffiths GO, Danson S & Reid AH (2020) Response to guadecitabine (SGI-110) combined with cisplatin and gemcitabine (GCG) in platinum refractory germ cell tumors (GCTs).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(15)
Sengupta S, Niazi T, Williams S, Davis ID, Stockler M, Martin AJ, Bracken K, Roncolato FT, McJannett M, Horvath L , Hughes S et al (2020) DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 16 (pp 204-204)
Niazi T, Williams S, Davis ID, Stockler MR, Martin AJ, Hague W, Bracken K, Gorzeman M, Roncolato F, Yip S , Horvath L et al (2020) DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate-A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(6)
Kuebler HR, Powles T, Meeks JJ, Galsky M, van der Heijdens MS, Nishiyama H, Al-Ahmadie H, Gupta A, Ye J, Donegan S , Ghiorghiu D et al (2020) A Phase 3, Randomized, Open-Label, Multicenter, Global Study of Efficacy and Safety of Durvalumab in Combination with Gemcitabine plus CiSPLATiN (G plus C) for Neoadjuvant Treatment Followed By Durvalumab Alone for Adjuvant Treatment in Muscle-Invasive Bladder Cancer (MiBC) (NiAGARA). ONCOLOGY RESEARCH AND TREATMENT, Vol. 43 (pp 82-82)
Tuthill M, Cappuccini F, Bryant RJ, Poulton I, Pollock E, Carter L, Verrill C, Meier A, Schmidt G, Catto JWF , Evans T et al (2020) Phase I/II open label nonrandomized safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 immunotherapy in combination with PD-1 checkpoint blockade in intermediate-risk localized or locally advanced prostate cancer and advanced metastatic prostate cancer.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(15)
Steinberg GD, Palou-Redorta J, Gschwend JE, Ben T, Loriot Y, Daneshmand S, Roupret M, Santiago-Walker AE, Switzky JC, Major C , Baig M et al (2020) A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guerin (BCG) therapy. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(6)
Khetrapal P, Catto J, Williams N, Ambler G, Sarpong R, Khan MS, Thurairaja R, Tan M, Feber A, Dixon S , Vasdev N et al (2020) THE ROLE OF WEARABLE DEVICES AND CPET IN PREDICTING MAJOR COMPLICATIONS AFTER RADICAL CYSTECTOMY. JOURNAL OF UROLOGY, Vol. 203 (pp E937-E937)
Williams S, Cumberbatch M, Kamat A, Kerr P, McGrath J, Djaladat H, Collins J, Jubber I, Packiam V, Steinberg G , Lee E et al (2020) REPORTING RADICAL CYSTECTOMY OUTCOMES FOLLOWING IMPLEMENTATION OF ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOLS: A SYSTEMATIC REVIEW AND INDIVIDUAL PATIENT DATA META-ANALYSIS. JOURNAL OF UROLOGY, Vol. 203 (pp E1087-E1088)
Griffin JL, Wei W, Heath P & Catto JWF (2019) Low Levels of Intra-Tumour Heterogeneity in Non-Muscle Invasive Bladder Cancer. JOURNAL OF PATHOLOGY, Vol. 249 (pp S12-S12)
Sathianathen N, Omer A, Moore C, Kasivisvanathan V, van den Bergh R, Punwani S, Kastner C, Barrett T, Murphy D, Catto J , MacPherson R et al (2019) NEGATIVE PREDICTIVE VALUE OF MULTI-PARAMETRIC MRI IN DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS. JOURNAL OF UROLOGY, Vol. 201(4) (pp E341-E341)
Wymer K, Sharma V, Borah B, Catto J, Thompson RH, Karnes RJ & Boorjian S (2019) COMPARATIVE COST-EFFECTIVENESS OF ACTIVE SURVEILLANCE, RADICAL PROSTATECTOMY, AND EXTERNAL BEAM RADIOTHERAPY: LESSONS FROM PROTECT. JOURNAL OF UROLOGY, Vol. 201(4) (pp E417-E418)
Miah S, Mangera A, Osman NI, Venugopal S, Catto J & Rosario D (2019) Islam and the Urinary Stoma: A Contemporary Theological and Urological Dilemma. European Urology Focus, Vol. 5(2) (pp 301-305)
Birtle A, Johnson M, Kockelbergh R, Jr KF, Catto J, Bryan R, Jones R, Chester J, Dolling D, Donovan J , French A et al (2018) Results of POUT - A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). BRITISH JOURNAL OF CANCER, Vol. 119(11) (pp 44-45)
Downing A, Wright P, Wilding S, Donnelly D, Hounsome L, Watson E, Wagland R, Butcher H, Kind P, Selby P , Catto J et al (2018) Patient-reported outcomes in men with advanced and localised disease: Results from the UK-wide Life After Prostate Cancer Diagnosis study. BRITISH JOURNAL OF CANCER, Vol. 119(11) (pp 11-11)
Mostafid H, Cresswell J, Griffiths L, Kelly J, Knight A, Catto J, Davenport K, Feber A, Knowles M, McGrath J , Cooke P et al (2018) Results of CALIBER: A phase II randomised feasibility trial of chemoablation with MMC versus surgical management in low risk non-muscle invasive bladder cancer (NMIBC). BRITISH JOURNAL OF CANCER, Vol. 119(11) (pp 39-39)
Crabb SJ, Danson SJ, Dunkley D, Kalevras M, Whitehead A, Hill S, Fines K, Robb C, Bennett J, Ksiazek L , Brown SL et al (2018) SPIRE: A phase Ib/ randomised IIa open label clinical trial combining guadecitabine with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer. ANNALS OF ONCOLOGY, Vol. 29
Crabb SJ, Danson SJ, Dunkley D, Kalevras M, Whitehead A, Hill S, Fines K, Robb C, Bennett J, Ksiazek L , Brown SL et al (2018) SPIRE: A phase Ib/ randomised IIa open label clinical trial combining guadecitabine with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer. Annals of Oncology, Vol. 29 (pp viii139-viii139)
Crabb SJ, Danson S, Catto J, McDowell C, Dunkley D, Huddart RA & Griffiths G (2018) SPIRE: A phase Ib/randomised IIa open label clinical trial combining guadecitabine (SGI-110) with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer.. Journal of Clinical Oncology, Vol. 36(15_suppl) (pp TPS4594-TPS4594)
Mostafid H, Cresswell J, Griffiths L, Kelly J, Knight A, Catto J, Davenport K, Feber A, Knowles M, McGrath J , Cooke P et al (2018) RESULTS OF CALIBER: A PHASE II RANDOMISED FEASIBILITY TRIAL OF CHEMOABLATION VERSUS SURGICAL MANAGEMENT IN LOW RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC). JOURNAL OF UROLOGY, Vol. 199(4) (pp E1231-E1231)
Voskuilen CS, Seiler R, Rink M, Poyet C, Noon AP, Roghmann F, Necchi A, Aziz A, Lavollé A, Young MJ , Marks P et al (2018) Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes. European Urology Focus
Mostafid H, Malde S, Mir-Kohler A, Bagnall P, Taylor J, Cresswell J & Catto J (2018) DISCHARGE OF LOW RISK NON MUSCLE INVASIVE BLADDER CANCER AFTER ONE YEAR: RESULTS OF A BAUS/BAUN NATIONAL SURVEY OF THE ADOPTION OF THE NICE BLADDER CANCER GUIDELINES RECOMMENDATIONS IN THE UK. JOURNAL OF UROLOGY, Vol. 199(4) (pp E98-E99)
Birtle A, Catto J, Johnson M, Kockelbergh R, Keeley F, Bryan R, Chester J, Jones R, Hill M, Donovan J , French A et al (2018) RESULTS OF POUT - A PHASE III RANDOMISED TRIAL OF PERI-OPERATIVE CHEMOTHERAPY VERSUS SURVEILLANCE IN UPPER TRACT UROTHELIAL CANCER (UTUC). JOURNAL OF UROLOGY, Vol. 199(4) (pp E213-E214)
Glaser A, Downing A, Wright P, Hounsome L, Kind P, Selby PJ, Wilding S, Donnelly D, Butcher H, Watson E , Richard W et al (2018) Life after prostate cancer diagnosis: One step beyond.. Journal of Clinical Oncology, Vol. 36(6_suppl) (pp 40-40)
Birtle AJ, Chester JD, Jones RJ, Johnson M, Hill M, Bryan RT, Catto J, Donovan J, French A, Harris C , Keeley F et al (2018) Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC).. Journal of Clinical Oncology, Vol. 36(6_suppl) (pp 407-407)
Newton RU, Hart NH, Kenfield SA, Chan JM, Courneya KS, Catto J, Finn SP, Greenwood R, Hughes DC, Mucci LA , Plymate SR et al (2017) Exercise medicine for metastatic castrate-resistant prostate cancer: a supervised, periodised, progressive and autoregulated program combining resistance and aerobic exercise - the INTERVAL-MCRPC prescription. BJU INTERNATIONAL, Vol. 120 (pp 14-14)
Pang KH, Rosario D, Morgan S & Catto J (2017) Evaluation of a short RNA within PCA3 in the predictive role for future cancer using non-malignant prostate biopsies. INTERNATIONAL JOURNAL OF UROLOGY, Vol. 24 (pp 144-144)
Gordon P & Catto J (2017) MP21-02 THE LONG TERM OUTCOMES FROM EARLY RE-RESECTION IN PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER. Journal of Urology, Vol. 197(4S)
Leslie T, Davies L, Elliott D, Brewster S, Sooriakumaran P, Rosario D, Catto J, Dudderidge T, Ahmed H, Emberton M , Hindley R et al (2017) PD56-08 THE PART TRIAL - A PHASE III STUDY COMPARING PARTIAL PROSTATE ABLATION VERSUS RADICAL PROSTATECTOMY (PART) IN INTERMEDIATE RISK PROSTATE CANCER – EARLY DATA FROM THE FEASIBILITY STUDY. Journal of Urology, Vol. 197(4S)
Lewis R, Maynard L, Catto J, Cresswell J, Feber A, Griffiths TRL, Kelly J, Knight A, Knowles M, McGrath J , Penegar S et al (2016) Recruitment aids for a phase II randomised trial in low risk bladder cancer. European Journal of Surgical Oncology (EJSO), Vol. 42(11) (pp S244-S244)
Pang KH, Catto J, Wilson S, Cumberbatch M & Lesbriel S (2016) Identification of N6-adenosine methylated RNAs by m6A-seq within prostate cancer. INTERNATIONAL JOURNAL OF UROLOGY, Vol. 23 (pp 131-131)
Birtle AJ, Maynard L, Johnson M, Kockelbergh R, Lewis R, Newton M, Jones RJ, Chester JD, Blacker A, Catto J & Hall E (2016) Acute toxicity data from POUT: A phase III randomized trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer.. Journal of Clinical Oncology, Vol. 34(15_suppl) (pp e16138-e16138)
Saad F, Kenfield SA, Chan JM, Hart NH, Courneya KS, Catto J, Finn SP, Greenwood R, Hughes DC, Mucci LA , Plymate SR et al (2016) Intense exercise for survival among men with metastatic castrate-resistant prostate cancer (INTERVAL – MCRPC): A Movember funded multicenter, randomized, controlled phase III study.. Journal of Clinical Oncology, Vol. 34(15_suppl) (pp TPS5092-TPS5092)
Noon A, Martissen JI, Pukkala E & Catto JWF (2015) Workplace patterns and urothelial bladder cancer phenotype - can occupation increase the risk of developing advanced disease?. BJU INTERNATIONAL, Vol. 115 (pp 11-11)
Noon A, Martissen JI, Pukkala E & Catto JWF (2015) Workplace patterns and urothelial bladder cancer phenotype - can occupation increase the risk of developing advanced disease?. BJU INTERNATIONAL, Vol. 115 (pp 8-8)
Stubendorff B, Wilhelm K, Posselt K, Catto J, Schaeffeler E, Schwab M, Hartmann A, Füssel S, Novotny V, Gajda M , Grimm M-O et al (2015) MP58-03 IDENTIFICATION OF SPECIFIC METHYLATION-BASED BIOMARKERS FOR THE ASSESSMENT OF THE METASTATIC RISK OF MUSCLE INVASIVE BLADDER CANCER. Journal of Urology, Vol. 193(4S)
Noon A, Liu Y, Shen J, Kuk C, Hermanns T, Azad A, Sweet J, Comperat E, van der Kwast TH, Catto JWF , Zlotta AR et al (2015) MP68-05 RESOLVING INTER-PATHOLOGIST VARIATION IN THE ASSIGNMENT OF GRADE USING WHOLE TRANSCRIPTOME ANALYSIS FOR PATIENTS WITH UROTHELIAL BLADDER CANCER. Journal of Urology, Vol. 193(4S)
Stubendorff B, Wilhelm K, Posselt K, Catto J, Harmann A, Fuessel S, Novotny V, Gajda M, Wunderlich H, Grimm M-O & Junker K (2014) Abstract 1358: Promoter hypermethylation of KISS1R, KiSS1, SEPT9 and CSAD as a prognostic biomarker panel to assess the metastatic potential of muscle invasive bladder tumors. Molecular and Cellular Biology
Cowling L, Varley C, Minshull T, Dickman M, Catto J & Southgate J (2014) 411: Epigenetic mechanisms of cadmium urothelial carcinogenesis. European Journal of Cancer, Vol. 50 (pp S98-S98)
Stubendorff B, Wilhelm K, Posselt K, Catto J, Hartmann A, Füssel S, Gajda M, Wunderlich H, Grimm M-O, Novotny V & Junker K (2014) MP28-06 PROMOTER HYPERMETHYLATION OF KISS1R, KISS1, SEPT9 AND CSAD AS A PROGNOSTIC BIOMARKER PANEL TO ASSESS THE METASTATIC POTENTIAL OF MUSCLE INVASIVE BLADDER TUMORS. Journal of Urology, Vol. 191(4S)
Stubendorff B, Wilhelm K, Dubey S, Dudziec E, Catto J, Gajda M, Wunderlich H, Grimm M-O & Junker K (2013) 1139 SPECIFIC CHANGES IN THE DNA METHYLATION PATTERN ENABLE AN EARLY ASSESSMENT OF THE METASTATIC RISK OF PRIMARY BLADDER TUMOURS. Journal of Urology, Vol. 189(4S)
Patel A, Catto J, Rosario D & O'Brien T (2013) 1295 SNAPSHOT OF TRANSURETHRAL RESECTION OF NEW BLADDER TUMOURS IN THE UK AUDIT (STUKA). Journal of Urology, Vol. 189(4S)
De Alejandro Montalvo J, Panoutsos G, Mahfouf M & Catto JW (2013) Radial basis function neural-fuzzy model for microarray signature identification. BIOINFORMATICS 2013 - Proceedings of the International Conference on Bioinformatics Models, Methods and Algorithms (pp 134-139)
Melling G, Hinsely EE, Catto JWF & Lambert DW (2012) 359 MicroRNA-145 Inhibits Myofibroblast Transdifferentiation by Regulating Extracellular Proteoglycan Versican. European Journal of Cancer, Vol. 48 (pp S87-S87)
Patel A, Fowler S, Rosario D, Catto J & O'Brien T (2012) Snapshot of transurethral resection in the UK audit (STUKA). BJU INTERNATIONAL, Vol. 109 (pp 34-34)
Blick C, Ramachandran A, Cranston D, Catto J & Harris AL (2012) Hypoxia regulated miRNAs in bladder cancer. BJU INTERNATIONAL, Vol. 109 (pp 25-25)
Stubendorff B, Dudziec E, Catto J, Sanjmyatav J, Gajda M, Wunderlich H, Grimm M-O & Junker K (2012) 1058 DIFFERENCES IN DNA METHYLATION PATTERN OF PRIMARY BLADDER TUMOURS CORRELATE WITH THEIR METASTATIC POTENTIAL. Journal of Urology, Vol. 187(4S)
Miah S, Dudziec E, Rosario D, Hamdy F & Catto J (2011) The utilisation of microrna in urine samples as a potential diagnostic and prognostic biomarker in bladder cancer. BRITISH JOURNAL OF SURGERY, Vol. 98(6) (pp E1-E2)
Khan KS, Glover M, Blizard S, Miah S, Rosario DP & Catto JW (2011) Role of expression of microrna machinery in bladder cancer. BRITISH JOURNAL OF SURGERY, Vol. 98(6) (pp E2-E2)
Ziegler M, Catto J, Riggs T, Gates E, Grodsky M & Wasvary H (2011) PREOPERATIVE HYPERGLYCEMIA AND DIABETES AS RISK FACTORS FOR ANASTOMOTIC LEAK FOLLOWING COLECTOMY: ANALYSIS FROM THE MICHIGAN SURGICAL QUALITY COLLABORATIVE (MSQC).. DISEASES OF THE COLON & RECTUM, Vol. 54(5) (pp E43-E44)
Stubendorff B, Dudziec E, Bourghol G, Catto J, Gajda M, Wunderlich H, Junker K & Grimm M-O (2011) 869 A SPECIFIC DNA METHYLATION PATTERN DISTINGUISHES BETWEEN METASTATIC AND NON-METASTATIC BLADDER CANCERS. Journal of Urology, Vol. 185(4S)
Miah SM, Dudziec E, Rosario D, Hamdy F & Catto J (2011) Urinary MicroRNAs as a diagnostic biomarker in bladder cancer. BRITISH JOURNAL OF SURGERY, Vol. 98 (pp 52-52)
Miah S, Dudziec E, Rosario D, Hamdy F & Catto J (2010) Optimisation of microRNA extraction from urine samples with a view for a diagnostic and prognostic test for bladder cancer. BJU INTERNATIONAL, Vol. 106(1) (pp 55-55)
Khan KS, Glover M, Blizard S, Miah S, Rosario DJ & Catto JW (2010) Differential expression of microRNA processing machinery in Urothelial Carcinoma. BJU INTERNATIONAL, Vol. 106(1) (pp 54-54)
Roupret M, Hupertan V, Yates DR, Catto JW, Rehman I, Meuth M, Ricci S, Lacave R, Cancel-Tassin G, De la Taille A , Rozet F et al (2007) Molecular diagnosis of localized prostate cancer by quantitative methylation-specific PCR gene patterns in urine cells obtained by prostate massage. JOURNAL OF UROLOGY, Vol. 177(4) (pp 95-95)
Catto JW, Yates D, Rehman I, Meuth M, Abbod MF, Linkens D & Hamdy FC (2007) Development of a prognostic marker panel in bladder cancer using aberrant promoter methylation. JOURNAL OF UROLOGY, Vol. 177(4) (pp 295-296)
Roupret M, Hupertan V, Yates DR, Catto JW, Rehman I, Meuth M, Ricci S, Lacave R, Gattegno B, Chartier-Kastler E , Richard F et al (2007) Compared performance of microsatellite and methylation urinalysis in predicting recurrence in transitional cell carcinoma and definition of a diagnostic panel of markers by bayesian network analysis. JOURNAL OF UROLOGY, Vol. 177(4) (pp 296-296)
Catto JW, Abbod MF, Linkens D, Wild PJ, Herr A, Pilarsky C, Wissman C, Hartmann A & Hamdy FC (2007) Artificial intelligence re-analysis of gene array data identifies novel markers of urothelial cancer progression. JOURNAL OF UROLOGY, Vol. 177(4) (pp 297-298)
Van Oers JMM, Zwarthoff EC, Rehman I, Azzouzi A-R, Cussenot O, Meuth M, Hamdy FC & Catto JWF (2006) FGFR3 mutations have different effects on disease course in tumors from the bladder, ureter, and renal pelvis. CANCER RESEARCH, Vol. 66(8)
Hartmann A, Catto JW, Van Oers J, Burger M, Stoehr R, Wild PJ, Cussenot O, Azzouzi A-R, Meuth M, Hamdy FC & Zwarthoff E (2006) FGFR3 mutations in upper urinary tract tumors are independent from microsatellite instability and associated with favorable outcome and a lower rate of bladder cancer recurrence. CANCER RESEARCH, Vol. 66(8)
Yates DR, Rehman I, Meuth M, Cross S, Hamdy FC & Catto JW (2006) A gene promoter hypermethylation panel to detect transitional cell carcinoma (TCC) of the bladder. CANCER RESEARCH, Vol. 66(8)
Catto J, Rehman I, Dhawan D, Meuth M & Hamdy FC (2006) Epigenetic changes in urothelial cancer: A feature of the invasive phenotype and a novel therapeutic target. JOURNAL OF UROLOGY, Vol. 175(4) (pp 197-197)
Abbod MF, Catto JWF, Linkens DA, Wild PJ, Herr A, Wissmann C, Pilarsky C, Hartmann A, Hamdy FC & IEEE (2006) Artificial intelligence technique for gene expression profiling of urinary bladder cancer. 2006 3RD INTERNATIONAL IEEE CONFERENCE INTELLIGENT SYSTEMS, VOLS 1 AND 2 (pp 634-639)
Cross SS, Hollingbury FE, Lippitt JM, Catto JW, Hamdy EC & Winder SJ (2005) beta-dystroglycan is constitutively expressed at the intercellular junctions of epithelial cells and this expression is frequently absent in common cancers. JOURNAL OF PATHOLOGY, Vol. 205 (pp 6-6)
Rehman I, Azzouzi AR, Catto J, Allen S, Cross S, Feeley K, Eaton C, Meuth M & Hamdy FC (2004) Proteomic analysis of voided urine following prostatic massage reveals tumour specific alterations. JOURNAL OF UROLOGY, Vol. 171(4) (pp 286-286)
Connelly J & Gatto J (1995) Increasing aircraft survivability through explosives detection. Aircraft Engineering, Technology, and Operations Congress
Catto J & Van den Heuvel R () Shorter hospital stay with robotic surgery versus open surgery in bladder cancer. Medicom Conference Report EAU 2022, 1 July 2022 - 1 July 2022.

Posters

Khetrapal P, Catto J, Ambler G, Ricciardi F, Khan S, Feber A, Dixon S, Williams N, Ahmed I, Charlesworth P , Cumberbatch M et al (2022) PD42-02 RESULTS OF THE INTRACORPOREAL ROBOTIC VS OPEN CYSTECTOMY (IROC) MULTI-CENTRE RANDOMISED TRIAL.
Khetrapal P, Catto JWF, Williams N, Ambler G, Khan MS, Thurairaja R, Tan MEL, Feber A, Ahmed I, Dixon S , Vasdev N et al (2021) Comparing the ability of wearable devices and CPET to predict major complications following radical cystectomy.

Preprints

Jubber I, Morhardt DR, Griffin J, Cumberbatch M, Glover M, Zheng Y, Rehman I, Loynes C, Hussain SA, Renshaw SA , Leach SD et al (2023) Analysis of the Distal Urinary Tract in Larval and Adult Zebrafish Reveals Unrecognized Homology to the Human System, Cold Spring Harbor Laboratory.
Khetrapal P, Stafford R, Ó Scanaill P, Kocadog H, Timinis C, Chang A, Hadjivasiliou A, Liu Y, Gibbs O, Pickford E , Walker D et al () Domiciliary recovery after medicalization pathway (DREAMPath): a protocol for a prospective observational study to measure patient compliance with remote monitoring following discharge from hospital after major surgery. (Preprint), JMIR Publications Inc..

Teaching activities: James teaches undergraduate medical students weekly and organises various uro-oncology study days for post-graduate urologists and surgeons. James is an educational supervisor to three trainee urologist and PhD mentor to 8 students.

Professional activities and memberships

James is a member of the NCRI-CSG for Bladder and Kidney cancer, the EAU Scientific Congress Office and specialises in Uro-Oncology. He was part of the NICE Bladder Cancer Guideline development panel.

James is on the Trial Steering Groups for numerous trials including i). Life after prostate cancer (Funded by Prostate cancer UK and Movember – see https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30780-0/fulltext). ii). VANCE01 - A randomized phase I study to determine the safety and immunogenicity of ChAd-MVA vaccination compared to MVA alone with and without low dose cyclophosphamide in low and intermediate risk localised prostate cancer (Funded by European Union – see https://jitc.bmj.com/content/8/1/e000928), iii). POUT - A phase III randomised trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (Funded by CRUK – see https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30415-3/fulltext), iv). BladderPath - Image directed Redesign of Bladder Cancer Treatment Pathways (Funded by NIHR-HTA – see https://www.europeanurology.com/article/S0302-2838(21)00141-X/fulltext), and v). CALIBER - A phase II randomised feasibility study of Chemoresection and surgicAl management in Low rIsk non muscle invasive Bladder cancer (Funded by CRUK – see https://bjui-journals.onlinelibrary.wiley.com/doi/full/10.1111/bju.15038).